MYD88 L265P Somatic Mutation in WaldenstrÃ¶m's Ma

New England Journal of Medicine
367, 826-833
DOI: 10.1056/nejmoa1200710

Citation Report

#	Article	IF	Citations
1	Lymphoplasmacytic Lymphoma/WaldenstrÃ¶mâ€™s Macroglobulinemia. , 2008, , 475-486.		0
2	Diagnostic Workup of Small B Cell Lymphomas: A Laboratory Perspective. Lymphoma, 2012, 2012, 1-15.	0.2	12
4	MYD88 L265P Somatic Mutation in IgM MGUS. New England Journal of Medicine, 2012, 367, 2255-2257.	27.0	101
5	WaldenstrÃ¶m macroglobulinaemia: the key questions. British Journal of Haematology, 2013, 162, 295-303.	2.5	7
6	Cancer Genomics. , 2013, , .		4
7	Next-generation sequencing of cancer consensus genes in lymphoma. Leukemia and Lymphoma, 2013, 54, 1831-1835.	1.3	10
8	La maladie de WaldenstrÃ¶m ou macroglobulinÃ©mie. Revue Francophone Des Laboratoires, 2013, 2013, 73-82.	0.0	0
9	Genetic Factors and Pathogenesis of WaldenstrÃ¶mâ€™s Macroglobulinemia. Current Oncology Reports, 2013, 15, 450-456.	4.0	14
10	Aberrantly sustained PAX5 expression in plasma cell differentiation is a frequent feature in lymphoplasmacytic lymphoma but not marginal zone lymphoma in bone marrow. Journal of Hematopathology, 2013, 6, 169-177.	0.4	0
11	XIII. WaldenstrÃ¶m's macroglobulinaemia: an indolent Bâ€cell lymphoma with distinct molecular and clinical features. Hematological Oncology, 2013, 31, 76-80.	1.7	13
13	WaldenstrÃ¶mâ€™s macroglobulinemia: Treatment approaches for newly diagnosed and relapsed disease. Transfusion and Apheresis Science, 2013, 49, 19-23.	1.0	9
14	MyD88 and its divergent toll in carcinogenesis. Trends in Immunology, 2013, 34, 379-389.	6.8	75
15	Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes. Journal of Autoimmunity, 2013, 45, 15-23.	6.5	3
16	Development of high-resolution melting analysis for the detection of the MYD88 L265P mutation. Clinical Biochemistry, 2013, 46, 385-387.	1.9	19
18	Novel Treatment Options for WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, S310-S316.	0.4	11
19	Molecular bases of chronic lymphocytic leukemia in light of new treatments. Immunology Letters, 2013, 155, 51-55.	2.5	10
20	Survival in Monoclonal Gammopathy of Undetermined Significance and WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 187-190.	0.4	8
21	Recurrent Gene Mutations in CLL. Advances in Experimental Medicine and Biology, 2013, 792, 87-107.	1.6	8

#	Article	IF	Citations
22	Targeting the Toll-like Receptor/Interleukin 1 Receptor Pathway in Human Diseases: Rational Design of MyD88 Inhibitors. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 222-226.	0.4	25
23	Newly Identified Mechanisms in B-Cell Non-Hodgkin Lymphomas Uncovered by Next-Generation Sequencing. Seminars in Hematology, 2013, 50, 303-313.	3.4	17
24	Next-Generation Sequencing in Chronic Lymphocytic Leukemia. Seminars in Hematology, 2013, 50, 286-295.	3.4	16
25	Genome sequencing of lymphoid malignancies. Blood, 2013, 122, 3899-3907.	1.4	60
26	Genomic Studies Have Identified Multiple Mechanisms of Genetic Changes in WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 202-204.	0.4	8
27	CD20-negative low-grade B cell lymphoma showing immunophenotypic and genotypic features resembling plasma cell myeloma. Pathology Research and Practice, 2013, 209, 459-462.	2.3	1
28	NouveautÃ©s sur les hÃ©mopathies lymphoÃ¯des chroniques B matures. Immuno-Analyse Et Biologie Specialisee, 2013, 28, 174-182.	0.0	0
29	Emerging patterns of somatic mutations in cancer. Nature Reviews Genetics, 2013, 14, 703-718.	16.3	442
30	Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Medicine, 2013, 5, 47.	8.2	41
31	Fludarabine in Waldenstromâ€™s macroglobulinemia. Expert Review of Hematology, 2013, 6, 229-237.	2.2	2
32	JAKs and STATs in Immunity, Immunodeficiency, and Cancer. New England Journal of Medicine, 2013, 368, 161-170.	27.0	738
33	Nextâ€generation sequencing â€“ feasibility and practicality in haematology. British Journal of Haematology, 2013, 160, 736-753.	2.5	54
34	ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?. Cancer Discovery, 2013, 3, 35-43.	9.4	347
35	Blastic Plasmacytoid Dendritic Cell Neoplasm. Surgical Pathology Clinics, 2013, 6, 743-765.	1.7	6
36	Challenges in Consolidated Reporting of Hematopoietic Neoplasms. Surgical Pathology Clinics, 2013, 6, 795-806.	1.7	7
38	Comparative Response Assessment by Serum Immunoglobulin M M-Protein and Total Serum Immunoglobulin M After Treatment of Patients With WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 250-252.	0.4	9
39	Etiology of WaldenstrÃ¶m Macroglobulinemia: Genetic Factors and Immune-related Conditions. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 194-197.	0.4	10
40	Genomic Abnormalities of WaldenstrÃ¶m Macroglobulinemia and Related Low-Grade B-Cell Lymphomas. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 198-201.	0.4	18

#	Article	IF	Citations
41	The Bone Marrow Microenvironment in WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 218-221.	0.4	10
42	Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in WaldenstrÃ¶mâ€™s macroglobulinemia and related lymphoid neoplasms. Blood, 2013, 121, 2522-2528.	1.4	290
43	MYD88 L265P in WaldenstrÃ¶m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood, 2013, 121, 2051-2058.	1.4	368
44	Targeting pathological B cell receptor signalling in lymphoid malignancies. Nature Reviews Drug Discovery, 2013, 12, 229-243.	46.4	342
45	Lymphoma classification and the tools of our trade: an introduction to the 2012 USCAP Long Course. Modern Pathology, 2013, 26, S1-S14.	5.5	36
46	A genomic view of mosaicism and human disease. Nature Reviews Genetics, 2013, 14, 307-320.	16.3	527
47	MYD88 L265P is a marker highly characteristic of, but not restricted to, WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia, 2013, 27, 1722-1728.	7.2	238
48	Genetic aberrations of signaling pathways in lymphomagenesis: Revelations from next generation sequencing studies. Seminars in Cancer Biology, 2013, 23, 422-430.	9.6	50
50	Regulation of Hematopoietic Stem Cell Activity by Inflammation. Frontiers in Immunology, 2013, 4, 204.	4.8	124
51	Choice of Therapy for Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2013, 31, 291-293.	1.6	15
52	The Scientific Drunk and the Lamppost: Massive Sequencing Efforts in Cancer Discovery and Treatment. Science Signaling, 2013, 6, pe13.	3.6	64
53	Genomic stratification for the treatment of lymphomas. Hematology American Society of Hematology Education Program, 2013, 2013, 331-334.	2.5	2
54	IgM Multiple Myeloma. American Journal of Clinical Pathology, 2013, 140, 519-524.	0.7	19
55	WaldenstrÃ¶m's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, 24, vi155-vi159.	1.2	62
56	Mutational Analysis Identifies Residues Crucial for Homodimerization of Myeloid Differentiation Factor 88 (MyD88) and for Its Function in Immune Cells. Journal of Biological Chemistry, 2013, 288, 30210-30222.	3.4	45
57	MYD88 L265P Somatic Mutation. American Journal of Clinical Pathology, 2013, 140, 387-394.	0.7	52
58	Next-generation Sequencing Discoveries in Lymphoma. Advances in Anatomic Pathology, 2013, 20, 110-116.	4.3	15
59	WaldenstrÃ¶m Macroglobulinemia: Clinical and Immunological Aspects, Natural History, Cell of Origin, and Emerging Mouse Models. ISRN Hematology, 2013, 2013, 1-25.	1.6	23

#	Article	IF	Citations
60	Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. American Journal of Hematology, 2013, 88, 948-954.	4.1	45
61	Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, <scp>IGHV</scp> mutations, and survival. A study of 76 cases. Histopathology, 2013, 62, 876-893.	2.9	12
62	Improved accuracy of discrimination between IgM Multiple Myeloma and WaldenstrÃ¶m Macroglobulinaemia by testing for <scp>MYD</scp>88 L265P mutations. British Journal of Haematology, 2013, 161, 902-904.	2.5	33
63	How to manage Waldenstromâ€™s macroglobulinemia. Leukemia, 2013, 27, 762-772.	7.2	42
64	Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer Journal, 2013, 3, e127-e127.	6.2	50
65	The MYDas touch of next-gen sequencing. Blood, 2013, 121, 2373-2374.	1.4	8
66	MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood, 2013, 121, 4504-4511.	1.4	214
67	A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in WaldenstrÃ¶m macroglobulinemia. Blood, 2013, 122, 1222-1232.	1.4	306
68	A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Blood, 2013, 121, 4434-4436.	1.4	50
69	Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary SjÃ¶grenâ€™s syndrome. Blood, 2013, 122, 4068-4076.	1.4	103
70	MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood, 2013, 122, 2284-2285.	1.4	56
71	Principles of pathway directed therapy. , 0, , 110-120.		0
72	Epigenetic Regulation of Toll-Like Receptor Signaling: Implications for Cancer Development. Medical Epigenetics, 2013, 1, 19-30.	262.3	6
73	Emerging targets in human lymphoma: targeting the MYD88 mutation. Blood and Lymphatic Cancer: Targets and Therapy, 2013, , 53.	2.7	2
74	New-generation sequencing (NGS) in hematologic oncology laboratories. Hematologie, 2013, 19, 112-122.	0.0	2
75	Candidate genes of Waldenström’s macroglobulinemia: current evidence and research. The Application of Clinical Genetics, 2013, 6, 33.	3.0	6
76	Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes. PLoS ONE, 2013, 8, e71120.	2.5	61
77	L265P Mutation of the MYD88 Gene Is Frequent in WaldenstrÃ¶mâ€™s Macroglobulinemia and Its Absence in Myeloma. PLoS ONE, 2013, 8, e80088.	2.5	38

#	Article	IF	Citations
78	MYD88 (L265P) Mutation in Malignant Lymphoma Using Formalin-Fixed Paraffin-Embedded Section. Journal of Clinical and Experimental Hematopathology: JCEH, 2013, 53, 175-177.	0.8	8
79	WaldenstrÃ¶m's macroglobulinemia/lymphoplasmacytic lymphoma. , 0, , 138-154.		0
80	Pyrosequencing as a Fast and Reliable Method in Detecting the MYD88 p.L265P Mutation in Decalcified Formalin-Fixed and Paraffin-Embedded Tissues. Annals of Laboratory Medicine, 2014, 34, 170-173.	2.5	1
81	Pathology of Indolent B-Cell Neoplasms Other than Follicular Lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2014, 54, 11-22.	0.8	9
82	MacroglobulinÃ©mie de WaldenstrÃ¶mÂ: de Jan Gosta Ã MYD88. Hematologie, 2014, 20, 23-25.	0.0	0
83	Current and future therapeutic approach for WaldenstrÃ¶mâ€™s macroglobulinemia. Immunotherapy, 2014, 6, 333-348.	2.0	1
84	The emerging roles of ARID1A in tumor suppression. Cancer Biology and Therapy, 2014, 15, 655-664.	3.4	200
85	ASH Update 2013: chronic lymphocytic leukemia and indolent lymphoma. Memo - Magazine of European Medical Oncology, 2014, 7, 141-143.	0.5	1
86	Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma. Blood Cancer Journal, 2014, 4, e183-e183.	6.2	67
87	MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in WaldenstrÃ¶mâ€™s Macroglobulinemia. Leukemia, 2014, 28, 1799-1803.	7.2	20
88	Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations. Blood Cancer Journal, 2014, 4, e266-e266.	6.2	11
89	Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leukemia and Lymphoma, 2014, 55, 1968-1979.	1.3	23
90	Clonotypic Analysis of Immunoglobulin Heavy Chain Sequences in Patients with WaldenstrÃ¶mâ€™s Macroglobulinemia: Correlation withMYD88L265P Somatic Mutation Status, Clinical Features, and Outcome. BioMed Research International, 2014, 2014, 1-6.	1.9	14
91	Diagnosis of Splenic B-Cell Lymphomas in the Bone Marrow: A Review of Histopathologic, Immunophenotypic, and Genetic Findings. Archives of Pathology and Laboratory Medicine, 2014, 138, 1295-1301.	2.5	19
92	Absence of somatic MYD88 L265P mutations in patients with primary Sjogrenâ€™s syndrome. Genes and Immunity, 2014, 15, 54-56.	4.1	5
93	Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis. Hematology American Society of Hematology Education Program, 2014, 2014, 113-118.	2.5	34
94	BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. Hematology American Society of Hematology Education Program, 2014, 2014, 125-134.	2.5	31
95	MYD88 L265P Mutations Are Correlated with 6q Deletion in Korean Patients with WaldenstrÃ¶m Macroglobulinemia. BioMed Research International, 2014, 2014, 1-7.	1.9	8

#	Article	IF	Citations
96	Multiparameter flow cytometry for the identification of the WaldenstrÃ¶mâ€™s clone in IgM-MGUS and WaldenstrÃ¶mâ€™s Macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia, 2014, 28, 166-173.	7.2	76
97	SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity. Nucleic Acids Research, 2014, 42, 7591-7610.	14.5	43
98	Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma. Leukemia and Lymphoma, 2014, 55, 1402-1403.	1.3	16
99	SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia, 2014, 28, 108-117.	7.2	200
100	Exome sequencing reveals frequent inactivating mutations inARID1A, ARID1B, ARID2andARID4Ain microsatellite unstable colorectal cancer. International Journal of Cancer, 2014, 135, 611-623.	5.1	107
101	High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia, 2014, 28, 719-720.	7.2	91
102	Longâ€term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. American Journal of Hematology, 2014, 89, 237-242.	4.1	68
103	Advances in the Discovery of Small-Molecule IRAK4 Inhibitors. Annual Reports in Medicinal Chemistry, 2014, 49, 117-133.	0.9	17
104	Personalized lymphoma diagnosis and treatment: recent advances. Diagnostic Histopathology, 2014, 20, 431-439.	0.4	0
105	Diseaseâ€specific mutations in mature lymphoid neoplasms: Recent advances. Cancer Science, 2014, 105, 623-629.	3.9	14
106	Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factorSPIBin WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2014, 166, 677-689.	2.5	16
107	IRAK4 Dimerization and trans -Autophosphorylation Are Induced by Myddosome Assembly. Molecular Cell, 2014, 55, 891-903.	9.7	108
108	Multiview Clustering on PPI Network for Gene Selection and Enrichment from Microarray Data. , 2014, , .		3
109	Schnitzler's syndrome: lessons from 281 cases. Clinical and Translational Allergy, 2014, 4, 41.	3.2	92
110	Elevated risk of venous but not arterial thrombosis in WaldenstrÃ¶m macroglobulinemia/lymphoplasmacytic lymphoma. Journal of Thrombosis and Haemostasis, 2014, 12, 1816-1821.	3.8	15
111	Dual function of MyD88 in inflammation and oncogenesis. Current Opinion in Oncology, 2014, 26, 86-91.	2.4	19
112	New Immunohistochemistry for B-Cell Lymphoma and Hodgkin Lymphoma. Archives of Pathology and Laboratory Medicine, 2014, 138, 1666-1672.	2.5	21
113	Consequences of the recurrent MYD88L265P somatic mutation for B cell tolerance. Journal of Experimental Medicine, 2014, 211, 413-426.	8.5	81

#	Article	IF	Citations
114	Rare Lymphomas. , 2014, , .		0
115		0.6	0
116	Bruton's tyrosine kinase inhibitors. Current Opinion in Oncology, 2014, 26, 463-468.	2.4	9
117	Detection of MYD88 L265P Mutation by Real-Time Allele-Specific Oligonucleotide Polymerase Chain Reaction. Applied Immunohistochemistry and Molecular Morphology, 2014, 22, 768-773.	1.2	28
118	<scp>MYD</scp>88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. British Journal of Haematology, 2014, 167, 506-513.	2.5	71
119	Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. Seminars in Cancer Biology, 2014, 24, 33-42.	9.6	80
120	Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. Leukemia Research, 2014, 38, 866-873.	0.8	20
121	The Pathogenesis of Chronic Lymphocytic Leukemia. Annual Review of Pathology: Mechanisms of Disease, 2014, 9, 103-118.	22.4	81
122	The Yin and Yang of Toll-like receptors in cancer. Oncogene, 2014, 33, 3485-3495.	5.9	266
123	IgG-lymphoplasmacytic lymphoma following polycythemia vera: JAK2 V617F and MYD88 L265P mutations separated in the same house. Annals of Hematology, 2014, 93, 1605-1607.	1.8	8
124	Targeting Bruton's tyrosine kinase in B cell malignancies. Nature Reviews Cancer, 2014, 14, 219-232.	28.4	420
125	Emergency granulopoiesis. Nature Reviews Immunology, 2014, 14, 302-314.	22.7	625
126	The genomic landscape of WaldenstrÃ¶m macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood, 2014, 123, 1637-1646.	1.4	394
127	MYD88-independent growth and survival effects of Sp1 transactivation in WaldenstrÃ¶m macroglobulinemia. Blood, 2014, 123, 2673-2681.	1.4	16
128	Molecular Testing in Cancer. , 2014, , .		2
129	Toll-like receptors and B cells: functions and mechanisms. Immunologic Research, 2014, 59, 12-22.	2.9	84
130	WaldenstrÃ¶m macroglobulinemia: from biology to treatment. Expert Review of Hematology, 2014, 7, 157-168.	2.2	16
131	The TLR and IL-1 signalling network at a glance. Journal of Cell Science, 2014, 127, 2383-90.	2.0	132

#	Article	IF	Citations
132	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nature Genetics, 2014, 46, 176-181.	21.4	624
134	Detection of MYD88 L265P in peripheral blood of patients with WaldenstrÃ¶mâ€™s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Leukemia, 2014, 28, 1698-1704.	7.2	100
135	Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4762-8.	7.1	34
136	Guidelines on the diagnosis and management of <scp>W</scp>aldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2014, 165, 316-333.	2.5	52
137	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood, 2014, 123, 3790-3796.	1.4	97
138	Schnitzler's syndrome; a case highlighting the complications of long-standing acquired autoinflammation. European Journal of Dermatology, 2014, 24, 405-406.	0.6	6
139	Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders. Leukemia, 2014, 28, 447-449.	7.2	17
140	B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica, 2014, 99, 222-231.	3.5	52
141	Cancers in People with HIV and AIDS. , 2014, , .		2
142	Assembly and localization of Toll-like receptor signalling complexes. Nature Reviews Immunology, 2014, 14, 546-558.	22.7	653
143	Toll-like receptors in the pathogenesis of human B cell malignancies. Journal of Hematology and Oncology, 2014, 7, 57.	17.0	54
144	Section II: Hematolymphoid malignancies. Current Problems in Cancer, 2014, 38, 159-174.	2.0	3
145	The tumour microenvironment in B cell lymphomas. Nature Reviews Cancer, 2014, 14, 517-534.	28.4	417
146	Targetable activating mutations are very frequent in GCB and ABC diffuse large Bâ€cell lymphoma. Genes Chromosomes and Cancer, 2014, 53, 144-153.	2.8	76
147	The diversity of diffuse large B-cell lymphoma in extranodal sites: overview and update. Journal of Hematopathology, 2014, 7, 57-70.	0.4	6
148	Small B-cell lymphomas of the spleen: how to tell them apart. Journal of Hematopathology, 2014, 7, 109-121.	0.4	7
150	Evolving Understanding of the CLL Genome. Seminars in Hematology, 2014, 51, 177-187.	3.4	24
151	CD79B and MYD88 mutations in diffuse large B-cell lymphoma. Human Pathology, 2014, 45, 556-564.	2.0	43

#	Article	IF	Citations
152	Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma. Experimental and Molecular Pathology, 2014, 97, 57-65.	2.1	10
153	Low-grade B-cell lymphoma presenting primarily in the bone marrow. Human Pathology, 2014, 45, 1379-1387.	2.0	5
154	Molecular lesions in B-cell lymphoproliferative disorders: recent contributions from studies utilizing high-throughput sequencing techniques. Leukemia and Lymphoma, 2014, 55, 19-30.	1.3	5
155	Overview on clinical trials in Waldenstrom's macroglobulinemia. Clinical Investigation, 2014, 4, 1139-1154.	0.0	0
156	Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in WaldenstrÃ¶m macroglobulinemia. Blood, 2014, 123, 2791-2796.	1.4	337
157	WaldenstrÃ¶m macroglobulinemia: genetics dictates clinical course. Blood, 2014, 123, 2750-2751.	1.4	2
158	Hallway gossip between Ras and PI3K pathways. Blood, 2014, 123, 2751-2753.	1.4	2
159	C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood, 2014, 123, 4120-4131.	1.4	187
160	Gamma heavy chain disease lacks the MYD88 L265p mutation associated with lymphoplasmacytic lymphoma. Haematologica, 2014, 99, e154-e155.	3.5	8
161	WaldenstrÃ¶m macroglobulinemia at 70. International Journal of Hematologic Oncology, 2014, 3, 253-266.	1.6	0
162	Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica, 2014, 99, 497-504.	3.5	142
163	The <scp>BCL</scp>2 antagonist <scp>ABT</scp>â€199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in <scp>CXCR</scp>4^{Wildâ€type} and <scp>CXCR</scp>4<scp>^{WHIM}</scp> mutated Waldenstrom macroglobulinaemia cells. British Journal of Haematology, 2015, 170, 134-138.	2.5	63
164	Ibrutinib: another weapon in our arsenal against lympho-proliferative disorders. Expert Opinion on Pharmacotherapy, 2015, 16, 2715-2718.	1.8	3
165	Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood, 2015, 125, 992-998.	1.4	47
166	The cellular origin and malignant transformation of WaldenstrÃ¶m macroglobulinemia. Blood, 2015, 125, 2370-2380.	1.4	80
167	Macro-Quest. Blood, 2015, 125, 2318-2319.	1.4	3
168	Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution. Haematologica, 2015, 100, 7-16.	3.5	54
169	Role of Complement in Autoimmune Hemolytic Anemia. Transfusion Medicine and Hemotherapy, 2015, 42, 303-310.	1.6	53

#	Article	IF	Citations
170	The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica, 2015, 100, 1495-1507.	3.5	81
171	Lack of myeloid differentiation primary response protein MyD88 L265P mutation in primary cutaneous marginal zone lymphoma. British Journal of Dermatology, 2015, 173, 1527-1528.	1.5	11
172	Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology. Cancer Control, 2015, 22, 158-166.	1.8	16
173	Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms. Biomarker Insights, 2015, 10s3, BMI.S22434.	2.5	2
174	<scp>MYD</scp>88 L265P and <scp>CXCR</scp>4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. British Journal of Haematology, 2015, 169, 795-803.	2.5	90
175	Targeting immune checkpoints in lymphoma. Current Opinion in Hematology, 2015, 22, 337-342.	2.5	38
176	MYD88 (L265P) Somatic Mutation in Marginal Zone B-cell Lymphoma. American Journal of Surgical Pathology, 2015, 39, 644-651.	3.7	76
177	Waldenstrom Macroglobulinemia an Auto-inflammatory Syndrome? Efficacy of Tocilizumab: A Case Report. Journal of Molecular Biomarkers & Diagnosis, 2015, 06, .	0.4	0
178	Immunophenotyping of WaldenstrÃ¶ms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications. PLoS ONE, 2015, 10, e0122338.	2.5	17
179	Nodal Marginal Zone Large B-Cell Lymphoma with Burkitt Translocation and Complex Chromosomal Changes Associated with Overexpression of BCL2, MYC, and BCL6. Journal of Clinical and Experimental Hematopathology: JCEH, 2015, 55, 175-180.	0.8	1
180	Contribution of Genetic Factors to SjÃ¶grenâ€™s Syndrome and SjÃ¶grenâ€™s Syndrome Related Lymphomagenesis. Journal of Immunology Research, 2015, 2015, 1-12.	2.2	31
181	Red Blood Cell Destruction in Autoimmune Hemolytic Anemia: Role of Complement and Potential New Targets for Therapy. BioMed Research International, 2015, 2015, 1-11.	1.9	74
183	New Insights in Prognosis and Therapy of Chronic Lymphocytic Leukaemia. , 0, , .		0
184	How I treat WaldenstrÃ¶m macroglobulinemia. Blood, 2015, 126, 721-732.	1.4	165
185	WaldenstrÃ¶m macroglobulinemia: 2015 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2015, 90, 346-354.	4.1	36
187	WaldenstrÃ¶m macroglobulinemia: What a hematologist needs to know. Blood Reviews, 2015, 29, 301-319.	5.7	37
188	Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. Clinical Cancer Research, 2015, 21, 3986-3994.	7.0	172
189	A novel MYD88 mutation, L265RPP, in WaldenstrÃ¶m macroglobulinemia activates the NF-Î°B pathway to upregulate Bcl-xL expression and enhances cell survival. Blood Cancer Journal, 2015, 5, e314-e314.	6.2	15

#	Article	IF	Citations
190	The molecular pathogenesis of Bâ€cell nonâ€Hodgkin lymphoma. European Journal of Haematology, 2015, 95, 280-293.	2.2	22
191	Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies. Annals of the New York Academy of Sciences, 2015, 1358, 82-94.	3.8	36
192	Clinical presentation and treatment responses in IgM-related AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 229-235.	3.0	19
193	Overview: A New Era of Cancer Genomics in Lymphoid Malignancies. Oncology, 2015, 89, 4-6.	1.9	14
194	Biology, Prognosis, and Therapy of WaldenstrÃ¶m Macroglobulinemia. Cancer Treatment and Research, 2015, 165, 177-195.	0.5	17
195	One-step molecular detection of the MYD88 L265P mutation by unlabeled probe genotyping analysis. Molecular and Cellular Probes, 2015, 29, 74-77.	2.1	2
196	Lymph Node. , 2015, , 591-628.		1
197	Extramedullary WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2015, 90, 100-104.	4.1	47
198	Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2015, 21, 2538-2545.	7.0	19
199	MYD88 Expression and L265P Mutation in Mature B-Cell Non-Hodgkin Lymphomas. Genetic Testing and Molecular Biomarkers, 2015, 19, 372-378.	0.7	8
200	IRAK signalling in cancer. British Journal of Cancer, 2015, 112, 232-237.	6.4	119
201	Ibrutinib for the treatment of WaldenstrÃ¶m macroglobulinemia. Expert Review of Hematology, 2015, 8, 569-579.	2.2	14
203	Ibrutinib in B lymphoid malignancies. Expert Opinion on Pharmacotherapy, 2015, 16, 1879-1887.	1.8	28
204	Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America, 2015, 29, 455-471.	2.2	81
205	Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and nonâ€Hodgkin lymphoma. British Journal of Haematology, 2015, 170, 445-456.	2.5	76
206	Successful treatment of refractory cold hemagglutinemia in MYD88 L265P mutation-negative WaldenstrÃ¶mâ€™s macroglobulinemia with bortezomib. International Journal of Hematology, 2015, 102, 238-243.	1.6	3
207	Molecular deregulation of signaling in lymphoid tumors. European Journal of Haematology, 2015, 95, 257-269.	2.2	6
208	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma in the Bone Marrow. American Journal of Clinical Pathology, 2015, 143, 797-806.	0.7	31

#	Article	IF	Citations
209	Pathology of B-Cell Lymphomas: Diagnosis and Biomarker Discovery. Cancer Treatment and Research, 2015, 165, 27-50.	0.5	10
210	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2015. Acta Haematologica Polonica, 2015, 46, 159-211.	0.3	0
211	The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. Seminars in Cancer Biology, 2015, 34, 22-35.	9.6	40
212	Genetics of multiple myeloma: another heterogeneity level?. Blood, 2015, 125, 1870-1876.	1.4	107
213	MyD-88 L265P MUTATIONS ARE PRESENT IN SOME CASES OF VITREORETINAL LYMPHOMA. Retina, 2015, 35, 624-627.	1.7	37
214	Ibrutinib in Previously Treated WaldenstrÃ¶mâ€™s Macroglobulinemia. New England Journal of Medicine, 2015, 372, 1430-1440.	27.0	810
215	The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstromâ€™s Macroglobulinemia. Leukemia, 2015, 29, 169-176.	7.2	180
216	Small cell B-cell lymphoma. Diagnostic Histopathology, 2015, 21, 383-390.	0.4	1
217	Bingâ€“Neel syndrome: Two unexpected cases and a review of the literature. Journal of the Neurological Sciences, 2015, 356, 19-26.	0.6	7
218	Significance ofMYD88L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia. Archives of Pathology and Laboratory Medicine, 2015, 139, 1035-1041.	2.5	25
219	Emerging therapeutic options for WaldenstrÃ¶m macroglobulinemia/lymphoplasmacytic lymphoma. Expert Review of Anticancer Therapy, 2015, 15, 1143-1156.	2.4	5
220	<scp>CXCR</scp>4 <scp>WHIM</scp>â€like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant <scp>MYD</scp>88^{L265P}â€directed survival signalling in <scp>W</scp>aldenstrÃ¶m macroglobulinaemia cells. British Journal of Haematology, 2015, 168, 701-707.	2.5	95
221	Overall survival and competing risks of death in patients withÂ<scp>W</scp>aldenstrÃ¶m macroglobulinaemia: an analysis of the <scp>S</scp>urveillance, <scp>E</scp>pidemiology and <scp>E</scp>nd <scp>R</scp>esults database. British Journal of Haematology, 2015, 169, 81-89.	2.5	110
222	Targeted inhibition of the deubiquitinating enzymes, <scp>USP</scp>14 and <scp>UCHL</scp>5, induces proteotoxic stress and apoptosis in <scp>W</scp>aldenstrÃ¶m macroglobulinaemia tumour cells. British Journal of Haematology, 2015, 169, 377-390.	2.5	55
223	Sarcoidosis Presenting As Lateâ€Onset Dementia: Are Cerebrospinal Fluid Biomarkers Analyses Helpful?. Journal of the American Geriatrics Society, 2015, 63, 198-200.	2.6	1
224	Persistent Dizziness. Journal of the American Geriatrics Society, 2015, 63, 197-198.	2.6	0
225	Alleleâ€specific <scp>PCR</scp> is a powerful tool for the detection of the <scp>MYD</scp>88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples. British Journal of Haematology, 2015, 171, 145-148.	2.5	14
226	Waldenstrom macroglobulinemia: prognosis and management. Blood Cancer Journal, 2015, 5, e394-e394.	6.2	41

#	Article	IF	Citations
227	Phase II clinical trials for Waldenstromâ€™s macroglobulinemia. Expert Opinion on Orphan Drugs, 2015, 3, 537-547.	0.8	0
228	Bruton's tyrosine kinase inhibitors in Bâ€cell nonâ€Hodgkin's lymphomas. Clinical Pharmacology and Therapeutics, 2015, 97, 469-477.	4.7	27
229	MYD88 Mutations and Response to Ibrutinib in WaldenstrÃ¶m's Macroglobulinemia. New England Journal of Medicine, 2015, 373, 584-586.	27.0	212
230	Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia, 2015, 29, 2338-2346.	7.2	34
231	MYD88 mutation analysis of a rare composite chronic lymphocyte leukemia and lymphoplasmacytic lymphoma by flow cytometry cell sorting. Annals of Hematology, 2015, 94, 1941-1944.	1.8	5
232	Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases. Frontiers of Medicine, 2015, 9, 288-303.	3.4	26
233	Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies. Blood Reviews, 2015, 29, 405-415.	5.7	38
234	Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype. Modern Pathology, 2015, 28, 1435-1447.	5.5	35
235	Selective interleukin-1 receptorâ€“associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy. Journal of Experimental Medicine, 2015, 212, 2189-2201.	8.5	140
236	MYD88 L265P mutations are correlated with 6q deletion in Korean patients with WaldenstrÃ¶m macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e124-e125.	0.4	0
237	Combination of serum microRNAâ€320a and microRNAâ€320b as a marker for <scp>W</scp>aldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2015, 90, E51-2.	4.1	8
238	Protein ubiquitination in lymphoid malignancies. Immunological Reviews, 2015, 263, 240-256.	6.0	23
239	SWI/SNF Chromatin Remodeling and Human Malignancies. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 145-171.	22.4	242
240	Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leukemia and Lymphoma, 2015, 56, 2141-2145.	1.3	77
241	MYD88mutant lymphoplasmacytic lymphoma/WaldenstrÃ¶m macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart. Leukemia and Lymphoma, 2015, 56, 420-425.	1.3	16
242	MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma. Modern Pathology, 2015, 28, 564-574.	5.5	59
243	Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation Guidelines for the Management of Indolent, Nonfollicular B-Cell Lymphoma (Marginal Zone, Lymphoplasmacytic, and Small Lymphocytic Lymphoma). Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 75-85.	0.4	32
244	WaldenstrÃ¶m macroglobulinemia and autoimmunity: what's the connection?. Leukemia and Lymphoma, 2015, 56, 845-846.	1.3	2

#	Article	IF	Citations
245	Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era. Leukemia and Lymphoma, 2015, 56, 1213-1222.	1.3	29
246	Malignancies of the Immune System: Use of Immunologic and Molecular Tumor Markers in Classification and Diagnostics. , 2016, , 1015-1035.		0
247	19. Translating science into therapy of lymphoma. , 2016, , 379-402.		0
248	12. WaldenstrÃ¶mâ€™s macroglobulinemia. , 2016, , 229-244.		0
249	Waldenström macroglobulinemia: biology, genetics, and therapy. Blood and Lymphatic Cancer: Targets and Therapy, 2016, Volume 6, 49-58.	2.7	6
250	Bing-Neel Syndrome: illustrative cases and comprehensive review of the literature. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017061.	1.3	17
251	Novel diagnostic tools: implication for the diagnosis, prognosis and understanding of haematological malignancies. Hematologie, 2016, 22, 66-72.	0.0	0
252	Cytogenetics in the management of lymphomas and lymphoproliferative disorders in adults and children: an update by the Groupe francophone de cytogÃ©nÃ©tique hÃ©matologique (GFCH). Annales De Biologie Clinique, 2016, 74, 568-587.	0.1	3
253	Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas. Blood Research, 2016, 51, 181.	1.3	11
254	Gain-of-Function Mutations in the Toll-Like Receptor Pathway: TPL2-Mediated ERK1/ERK2 MAPK Activation, a Path to Tumorigenesis in Lymphoid Neoplasms?. Frontiers in Cell and Developmental Biology, 2016, 4, 50.	3.7	16
255	The Role of Toll-Like Receptors in Hematopoietic Malignancies. Frontiers in Immunology, 2016, 7, 390.	4.8	82
256	Recent Progress in the Molecular Recognition and Therapeutic Importance of Interleukin-1 Receptor-Associated Kinase 4. Molecules, 2016, 21, 1529.	3.8	25
257	Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer Journal (Sudbury, Mass), 2016, 22, 34-39.	2.0	25
258	Central nervous system involvement by WaldenstrÃ¶m macroglobulinaemia (Bingâ€Neel syndrome): a multiâ€institutional retrospective study. British Journal of Haematology, 2016, 172, 709-715.	2.5	87
259	Mighty MyD88 in Health and Disease. Retina, 2016, 36, 429-431.	1.7	9
260	Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Modern Pathology, 2016, 29, 1118-1142.	5.5	36
261	PREVALENCE OF MYD88 L265P MUTATION IN HISTOLOGICALLY PROVEN, DIFFUSE LARGE B-CELL VITREORETINAL LYMPHOMA. Retina, 2016, 36, 624-628.	1.7	79
263	Positive selection and high sensitivity test for MYD88 mutations using locked nucleic acid. International Journal of Laboratory Hematology, 2016, 38, 133-140.	1.3	10

#	Article	IF	Citations
264	Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected WaldenstrÃ¶m macroglobulinemia/lymphoplasmacytic lymphoma. Leukemia Research, 2016, 51, 41-48.	0.8	5
265	B-cellâ€“specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. Blood, 2016, 127, 2732-2741.	1.4	99
266	Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity. Haematologica, 2016, 101, e361-e364.	3.5	36
267	Cold agglutinin disease. Hematology American Society of Hematology Education Program, 2016, 2016, 226-231.	2.5	87
268	The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients. Leukemia Research, 2016, 46, 85-88.	0.8	20
269	Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 395-403.e1.	0.4	18
271	Big insights from small volumes: deciphering complex leukocyte behaviors using microfluidics. Journal of Leukocyte Biology, 2016, 100, 291-304.	3.3	22
272	Dissecting a Hub for Immune Response: Modeling the Structure of MyD88. Structure, 2016, 24, 349-351.	3.3	5
274	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies. Modern Pathology, 2016, 29, 685-697.	5.5	55
276	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets. Leukemia and Lymphoma, 2016, 57, 1991-2013.	1.3	26
277	GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo. Blood, 2016, 127, 2723-2731.	1.4	52
278	Exome sequencing reveals recurrent germ line variants in patients with familial WaldenstrÃ¶m macroglobulinemia. Blood, 2016, 127, 2598-2606.	1.4	22
279	Optimizing therapy for nodal marginal zone lymphoma. Blood, 2016, 127, 2064-2071.	1.4	59
280	The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 2016, 127, 2375-2390.	1.4	5,965
281	Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood, 2016, 127, 2361-2364.	1.4	115
282	Transcriptome sequencing reveals a profile that corresponds to genomic variants in WaldenstrÃ¶m macroglobulinemia. Blood, 2016, 128, 827-838.	1.4	91
283	Mouse model of MYD88L265P-dependent DLBCL. Blood, 2016, 127, 2660-2661.	1.4	1
284	WM, MYD88, and CXCR4: following the thread. Blood, 2016, 128, 746-748.	1.4	13

#	Article	IF	Citations
285	Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. Haematologica, 2016, 101, 1002-1009.	3.5	43
286	Current therapy guidelines for Waldenstrom's macroglobulinaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 194-205.	1.7	5
287	Monoclonal gammopathy of undetermined significance and WaldenstrÃ¶m's macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 187-193.	1.7	5
288	Inhibiting TLR9 and other UNC93B1-dependent TLRs paradoxically increases accumulation of MYD88L265P plasmablasts in vivo. Blood, 2016, 128, 1604-1608.	1.4	10
289	â€œAll the soarings of my mind begin in my blood:â€•central nervous system complication of WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2016, 91, 1057-1060.	4.1	0
290	Plasma Cell Dyscrasias. Cancer Treatment and Research, 2016, , .	0.5	3
291	Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment. Cancer Treatment and Research, 2016, 169, 321-361.	0.5	6
292	Bone marrow microenvironment in Waldenstrom's Macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 148-155.	1.7	10
293	Prognostic factors and indications for treatment of WaldenstrÃ¶m's Macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 179-186.	1.7	12
294	Origin of Waldenstrom's macroglobulinaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 136-147.	1.7	17
295	Future therapeutic options for patients with WaldenstrÃ¶m macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 206-215.	1.7	4
296	NF-ÎºB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions. Seminars in Cancer Biology, 2016, 39, 40-48.	9.6	60
297	Histological transformation to diffuse large Bâ€cell lymphoma in patients with WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2016, 91, 1032-1035.	4.1	53
298	Molecular Pathology. Surgical Pathology Clinics, 2016, 9, 489-521.	1.7	3
299	Chronic lymphocytic leukemia: Time to go past genomics?. American Journal of Hematology, 2016, 91, 518-528.	4.1	13
300	Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization. Protein Engineering, Design and Selection, 2016, 29, 347-354.	2.1	18
301	MALT lymphoma: A paradigm of NF-ÎºB dysregulation. Seminars in Cancer Biology, 2016, 39, 49-60.	9.6	69
302	Genetic evolution in chronic lymphocytic leukaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 67-78.	1.7	1

#	Article	IF	Citations
303	Rewired NFÎºB signaling as a potentially actionable feature of activated Bâ€cellâ€like diffuse large Bâ€cell lymphoma. European Journal of Haematology, 2016, 97, 499-510.	2.2	17
304	Targeting cell adhesion and homing as strategy to cure WaldenstrÃ¶m's macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 161-168.	1.7	5
305	Novel therapeutic targets in Waldenstrom macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 216-228.	1.7	9
306	Toll-like receptors targeting technology for the treatment of lymphoma. Expert Opinion on Drug Discovery, 2016, 11, 1047-1059.	5.0	5
307	Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood, 2016, 127, 3035-3039.	1.4	34
308	Pathogenic role of B-cell receptor signaling and canonical NF-Îºb activation in mantle cell lymphoma. Blood, 2016, 128, 82-92.	1.4	141
309	HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood, 2016, 127, 3237-3252.	1.4	93
310	The genetics of nodal marginal zone lymphoma. Blood, 2016, 128, 1362-1373.	1.4	147
311	First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis. Blood, 2016, 127, 2936-2938.	1.4	17
312	Personalized Immunotherapy Targeting the Cancer Mutanome. , 2016, , 426-433.		1
313	Recommendations for the diagnosis and initial evaluation of patients with WaldenstrÃ¶m Macroglobulinaemia: A Task Force from the 8th International Workshop on WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2016, 175, 77-86.	2.5	61
314	Ibrutinib in WaldenstrÃ¶m macroglobulinemia: latest evidence and clinical experience. Therapeutic Advances in Hematology, 2016, 7, 179-186.	2.5	28
315	TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism. Cancer Research, 2016, 76, 6975-6987.	0.9	21
316	The role of stem cell transplantation in Waldenstrom's macroglobulinemia. Best Practice and Research in Clinical Haematology, 2016, 29, 229-240.	1.7	6
317	Preclinical models of WaldenstrÃ¶m's macroglobulinemia and drug resistance. Best Practice and Research in Clinical Haematology, 2016, 29, 169-178.	1.7	4
318	Plasma Cell Disorders. Primary Care - Clinics in Office Practice, 2016, 43, 677-691.	1.6	22
319	Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2016, 56, 71-78.	0.8	35
320	5. Follicular lymphoma. , 2016, , 75-100.		0

#	Article	IF	Citations
321	Old Dogs, New Tricks: Monogenic Autoinflammatory Disease Unleashed. Annual Review of Genomics and Human Genetics, 2016, 17, 245-272.	6.2	45
322	Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. Journal of Molecular Diagnostics, 2016, 18, 507-515.	2.8	144
323	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May HarborMYD88L265P Mutations. American Journal of Clinical Pathology, 2016, 145, 843-851.	0.7	43
324	Synchronous immunophenotypically and clonally distinct follicular lymphoma and marginal zone lymphoma with massive amyloid deposition. Human Pathology: Case Reports, 2016, 5, 10-17.	0.2	0
325	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016. Acta Haematologica Polonica, 2016, 47, 39-85.	0.3	10
326	Clonal B cells in WaldenstrÃ¶mâ€™s macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. Leukemia, 2016, 30, 1116-1125.	7.2	30
327	Dual NAMPT and BTK Targeting Leads to Synergistic Killing of WaldenstrÃ¶m Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clinical Cancer Research, 2016, 22, 6099-6109.	7.0	19
328	Clonal architecture of <scp>CXCR</scp>4 <scp>WHIM</scp>â€like mutations in WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2016, 172, 735-744.	2.5	122
329	Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. Expert Review of Molecular Diagnostics, 2016, 16, 461-472.	3.1	33
330	Bing Neel Syndrome in a Previously Untreated Patient With WaldenstrÃ¶m's Macroglobulinemia: Contribution of MYD88 L265P Mutation on Cerebrospinal Fluid. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, e7-e9.	0.4	10
331	Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. Current Treatment Options in Oncology, 2016, 17, 16.	3.0	12
332	Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leukemia and Lymphoma, 2016, 57, 2699-2701.	1.3	4
333	MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. Clinical Cancer Research, 2016, 22, 2755-2764.	7.0	55
334	HIV-associated Hematological Malignancies. , 2016, , .		4
335	The molecular pathogenesis of chronic lymphocytic leukaemia. Nature Reviews Cancer, 2016, 16, 145-162.	28.4	227
336	B-cell Non-Hodgkin Lymphomas with Plasmacytic Differentiation. Surgical Pathology Clinics, 2016, 9, 11-28.	1.7	11
337	Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenstrom macroglobulinemia. Haematologica, 2016, 101, e111-e115.	3.5	30
338	The role of next-generation sequencing in understanding the genomic basis of diffuse large B cell lymphoma and advancing targeted therapies. Expert Review of Hematology, 2016, 9, 255-269.	2.2	12

#	Article	IF	Citations
339	Genomic Landscape of CXCR4 Mutations in WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2016, 22, 1480-1488.	7.0	102
340	Adoptive B-cell transfer mouse model of human myeloma. Leukemia, 2016, 30, 962-966.	7.2	5
341	TCL1 expression patterns in WaldenstrÃ¶m macroglobulinemia. Modern Pathology, 2016, 29, 83-88.	5.5	4
342	The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 259-275.	2.8	97
343	Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leukemia and Lymphoma, 2016, 57, 1104-1113.	1.3	40
344	Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in WaldenstrÃ¶m macroglobulinemia. Oncogene, 2016, 35, 479-490.	5.9	13
345	Treatment of patients with WaldenstrÃ¶m macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 2017, 47, 35-49.	0.8	10
346	Plasma cell leukemia with t(11;14)(q13;q32) simulating lymphoplasmacytic lymphoma â€“ a diagnostic challenge solved by flow cytometry. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 66-69.	0.7	7
347	Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms. Archives of Pathology and Laboratory Medicine, 2017, 141, 341-354.	2.5	6
348	WaldenstrÃ¶m macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2017, 92, 209-217.	4.1	42
349	Another bidder (BDR) revisits. Blood, 2017, 129, 398-400.	1.4	8
350	Genomics of Multiple Myeloma. Journal of Clinical Oncology, 2017, 35, 963-967.	1.6	85
351	Regulation of Inflammation- and Infection-Driven Hematopoiesis. Trends in Immunology, 2017, 38, 345-357.	6.8	209
352	p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. Blood Reviews, 2017, 31, 251-259.	5.7	47
353	c-Myc dysregulation is a co-transforming event for nuclear factor-ÎºB activated B cells. Haematologica, 2017, 102, 883-894.	3.5	17
354	Acquired mutations associated with ibrutinib resistance in WaldenstrÃ¶m macroglobulinemia. Blood, 2017, 129, 2519-2525.	1.4	115
355	MYD88 L265P mutation in cutaneous involvement by WaldenstrÃ¶m macroglobulinemia. Journal of Cutaneous Pathology, 2017, 44, 625-631.	1.3	10
356	Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas. Expert Review of Molecular Diagnostics, 2017, 17, 623-632.	3.1	2

#	Article	IF	Citations
357	Serum IgM level as predictor of symptomatic hyperviscosity in patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2017, 177, 717-725.	2.5	58
358	Pathogenesis of lymphomas. , 2017, , 11-31.		2
359	Role of plasma cells in WaldenstrÃ¶m macroglobulinaemia. Pathology, 2017, 49, 337-345.	0.6	14
360	Small-Molecule Inhibitors of Brutonâ€™s Tyrosine Kinase. Topics in Medicinal Chemistry, 2017, , 75-104.	0.8	2
361	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. OncoImmunology, 2017, 6, e1321184.	4.6	23
362	2016 WHO Classification updateâ€"What's new in lymphoid neoplasms. International Journal of Laboratory Hematology, 2017, 39, 14-22.	1.3	16
363	Management of Lymphomas: A Case-Based Approach. , 2017, , .		0
364	Novel approaches to targeting MYD88 in WaldenstrÃ¶m macroglobulinemia. Expert Review of Hematology, 2017, 10, 739-744.	2.2	6
365	Current Status of Brutonâ€™s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Drugs and Aging, 2017, 34, 509-527.	2.7	34
366	Flow Cytometric Patterns of CD200 and CD1d Expression Distinguish CD10-Negative, CD5-Negative Mature B-Cell Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2017, 148, 33-41.	0.7	8
367	Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood, 2017, 130, 410-423.	1.4	163
368	Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry. Archives of Pathology and Laboratory Medicine, 2017, 141, 1236-1246.	2.5	20
369	The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. Blood, 2017, 130, 433-439.	1.4	50
370	IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	4.1	45
371	Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79. Haematologica, 2017, 102, e275-e277.	3.5	8
373	CSF analysis for protein biomarker identification in patients with leptomeningeal metastases from CNS lymphoma. Expert Review of Proteomics, 2017, 14, 363-372.	3.0	6
374	Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. Annals of Hematology, 2017, 96, 971-976.	1.8	26
375	Targeting of Bâ€cell receptor signalling in Bâ€cell malignancies. Journal of Internal Medicine, 2017, 282, 415-428.	6.0	37

#	Article	IF	Citations
376	WaldenstrÃ¶m Macroglobulinemia: Review of Pathogenesis and Management. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 252-262.	0.4	38
377	HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. OncoImmunology, 2017, 6, e1219825.	4.6	28
378	Pathology of nodal marginal zone lymphomas. Best Practice and Research in Clinical Haematology, 2017, 30, 50-55.	1.7	14
379	Ibrutinib for patients with rituximab-refractory WaldenstrÃ¶m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncology, The, 2017, 18, 241-250.	10.7	212
380	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood, 2017, 129, 473-483.	1.4	147
381	Current treatment options and investigational drugs for Waldenstromâ€™s Macroglobulinemia. Expert Opinion on Investigational Drugs, 2017, 26, 197-205.	4.1	12
382	Detection of theMYD88mutation by the combination of the allele-specific PCR and quenching probe methods. International Journal of Laboratory Hematology, 2017, 39, 163-168.	1.3	3
383	Diagnosis and Management of WaldenstrÃ¶m Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
384	Clonal B-cell lymphocytosis of marginal zone origin. Best Practice and Research in Clinical Haematology, 2017, 30, 77-83.	1.7	12
385	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica, 2017, 102, 43-51.	3.5	112
387	Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer Journal, 2017, 7, e617-e617.	6.2	45
388	Pattern of somatic mutations in patients with WaldenstrÃ¶m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica, 2017, 102, 2077-2085.	3.5	90
389	From WaldenstrÃ¶mâ€™s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. Blood Cancer Journal, 2017, 7, e591-e591.	6.2	31
390	First report of MYD88^{L265P} somatic mutation in IgM-associated light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 42-43.	3.0	10
391	Synergistic cooperation and crosstalk between MYD88L265P and mutations that dysregulate CD79B and surface IgM. Journal of Experimental Medicine, 2017, 214, 2759-2776.	8.5	38
392	Schnitzler Syndrome: a Review. Current Rheumatology Reports, 2017, 19, 46.	4.7	59
393	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ…ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017. Acta Haematologica Polonica, 2017, 48, 55-103.	0.3	5
394	Redundant and regulatory roles for Toll-like receptors inLeishmaniainfection. Clinical and Experimental Immunology, 2017, 190, 167-186.	2.6	35

#	Article	IF	Citations
395	TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. Clinical Cancer Research, 2017, 23, 6325-6335.	7.0	64
396	Nietypowe objawy kliniczne szpiczaka plazmocytowego. Acta Haematologica Polonica, 2017, 48, 189-194.	0.3	0
397	Pathways towards indolent B-cell lymphoma â€" Etiology and therapeutic strategies. Blood Reviews, 2017, 31, 426-435.	5.7	7
398	Dexamethasone, rituximab and cyclophosphamide for relapsedÂand/or refractory and treatmentâ€naÃ¯ve patients with Waldenstrom macroglobulinemia. British Journal of Haematology, 2017, 179, 98-105.	2.5	25
399	CXCL13 levels are elevated in patients with WaldenstrÃ¶m macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica, 2017, 102, e452-e455.	3.5	22
400	Diagnostik lymphatischer Neoplasien. Laboratoriums Medizin, 2017, 41, 285-297.	0.6	1
401	Cost-effectiveness analysis of ibrutinib in patients with WaldenstrÃ¶m macroglobulinemia in Italy. Journal of Market Access & Health Policy, 2017, 5, 1393308.	1.5	1
402	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88^{L265P} Diffuse Large B-Cell Lymphoma. Journal of Medicinal Chemistry, 2017, 60, 10071-10091.	6.4	45
404	Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 621-630.	0.4	5
405	Retrospective analysis of prognostic factors for WaldenstrÓ§m macroglobulinemia: a multicenter cooperative study in Japan. International Journal of Hematology, 2017, 106, 681-690.	1.6	3
406	Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nature Reviews Neurology, 2017, 13, 533-547.	10.1	188
407	Clinical Impact of the 2016 Update to the WHO Lymphoma Classification. Current Treatment Options in Oncology, 2017, 18, 45.	3.0	35
408	Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Modern Pathology, 2017, 30, 1338-1366.	5.5	36
409	Brutonâ€™s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives. Expert Opinion on Investigational Drugs, 2017, 26, 909-915.	4.1	30
411	Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia. Leukemia, 2017, 31, 1355-1362.	7.2	11
412	MALT lymphoma: Genetic abnormalities, immunological stimulation and molecular mechanism. Best Practice and Research in Clinical Haematology, 2017, 30, 13-23.	1.7	47
413	To select or not to select? The role of Bâ€cell selection in determining the <scp>MYD</scp>88 mutation status in WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2017, 176, 822-824.	2.5	22
414	Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. British Journal of Haematology, 2017, 177, 808-813.	2.5	13

#	Article	IF	Citations
415	Detection of L265P MYDâ€88 mutation in a series of clonal Bâ€cell lymphocytosis of marginal zone origin (CBLâ€MZ). Hematological Oncology, 2017, 35, 542-547.	1.7	10
416	Nodal marginal zone lymphoma: mutation status analyses of CD79A, CD79B, and MYD88 reveal no specific recurrent lesions. Leukemia and Lymphoma, 2017, 58, 979-981.	1.3	5
418	WaldenstrÃ¶m Macroglobulinaemia: Pathological Features and Diagnostic Assessment. , 2017, , 3-19.		0
419	Genetic Predisposition to WaldenstrÃ¶m Macroglobulinemia. , 2017, , 111-141.		0
420	Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS). , 2017, , 143-167.		0
421	Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains. , 2017, , 239-261.		0
422	Response Assessment in WaldenstrÃ¶mâ€™s Macroglobulinaemia. , 2017, , 265-275.		0
423	WaldenstrÃ¶mâ€™s Macroglobulinemia Immunophenotype. , 2017, , 21-34.		3
425	Signal Inhibitors in Waldenstromâ€™s Macroglobulinemia. , 2017, , 327-334.		0
426	Predispositions and Origins of Waldenstrom Macroglobulinemia: Implications from Genetic Analysis. , 2017, , 35-48.		0
427	Genetic and Signaling Abnormalities in Waldenstromâ€™s Macroglobulinemia. , 2017, , 53-65.		1
429	Waldenstromâ€™s Macroglobulinaemia: Immunosurveillance and the Immune Micro-environment. , 2017, , 83-94.		0
430	Epidemiology of WaldenstrÃ¶m Macroglobulinemia. , 2017, , 97-109.		1
431	Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies. Leukemia and Lymphoma, 2017, 58, 666-675.	1.3	18
432	Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2017, 179, 849-851.	2.5	11
433	Biology and Management of Unusual Plasma Cell Dyscrasias. , 2017, , .		0
434	Waldenstromâ€™s Macroglobulinemia. , 2017, , 71-93.		0
435	Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma. Human Pathology, 2017, 59, 70-79.	2.0	28

#	Article	IF	Citations
436	Primary Type3 (Non-ABC, Non-GCB) Subtype of Extranodal Diffuse Large B-Cell Lymphoma of the Thyroid Bearing No MYD88 Mutation by Padlock Probe Hybridization. Case Reports in Oncology, 2017, 10, 508-514.	0.7	1
437	Lymphoproliferative Tumors of the Ocular Adnexa. Asia-Pacific Journal of Ophthalmology, 2017, 6, 132-142.	2.5	35
438	Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma. Hematology American Society of Hematology Education Program, 2017, 2017, 371-378.	2.5	24
439	Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice. Blood Advances, 2017, 1, 2361-2374.	5.2	11
440	Toward personalized treatment in WaldenstrÃ¶m macroglobulinemia. Hematology American Society of Hematology Education Program, 2017, 2017, 365-370.	2.5	7
441	The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstromâ€™s Macroglobulinemia. International Journal of Molecular Sciences, 2017, 18, 2038.	4.1	1
442	Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstromâ€™s Macroglobulinemia. Case Reports in Hematology, 2017, 2017, 1-4.	0.4	1
443	New developments in the management of Waldenström macroglobulinemia. Cancer Management and Research, 2017, Volume 9, 73-83.	1.9	13
444	Ibrutinib-associated skin toxicity: a case of maculopapular rash in a 79-year old Caucasian male patient with relapsed Waldenstromâ€™s macroglobulinemia and review of the literature. Dermatology Reports, 2017, 9, 6976.	0.8	16
445	Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick. Journal of Clinical Oncology, 2017, 35, 1872-1878.	1.6	3
446	Genomics, Signaling, and Treatment of WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2017, 35, 994-1001.	1.6	76
447	Next-Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients With Lymphoid Malignancies. JCO Precision Oncology, 2017, 1, 1-13.	3.0	18
448	Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia. Journal of Clinical Oncology, 2017, 35, 2708-2715.	1.6	63
449	IGHV segment utilization in immunoglobulin gene rearrangement differentiates patients with anti-myelin-associated glycoprotein neuropathy from others immunoglobulin M-gammopathies. Haematologica, 2018, 103, e207-e210.	3.5	9
450	High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations. Leukemia, 2018, 32, 2412-2426.	7.2	53
451	Venetoclax: A new wave in hematooncology. Experimental Hematology, 2018, 61, 10-25.	0.4	73
452	Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood, 2018, 131, 2501-2505.	1.4	57
453	Morphology and Immunophenotype of Chronic Lymphocytic Leukemia. , 2018, , 79-98.		0

#	Article	IF	Citations
454	Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2018, 24, 3247-3252.	7.0	57
455	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with WaldenstrÃ¶m macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	1.8	71
456	Pseudo liposarcomatous plasma cells in a patient with liposarcoma and lymphoplasmacytic lymphoma. Clinical Case Reports (discontinued), 2018, 6, 529-530.	0.5	0
457	Pathology of Non-Hodgkin and Hodgkin Lymphomas. , 2018, , 773-826.		0
458	Inhibitors of the JAK/STAT Pathway, with a Focus on Ruxolitinib and Similar Agents. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 107-134.	0.1	1
459	How we manage patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2018, 181, 737-751.	2.5	8
460	BTK Inhibitors: Focus on Ibrutinib and Similar Agents. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 1-22.	0.1	0
461	Chemokines: a novel chronic GVHD target. Blood, 2018, 131, 1636-1638.	1.4	1
462	Lymphoma exosomes reprogram the bone marrow. Blood, 2018, 131, 1635-1636.	1.4	6
463	WaldenstrÃ¶mâ€™s Macroglobulinemia. Hematologic Malignancies, 2018, , 191-220.	0.2	2
464	Germline gain-of-function myeloid differentiation primary response geneâ€“88 (MYD88) mutation in a child with severe arthritis. Journal of Allergy and Clinical Immunology, 2018, 141, 1943-1947.e9.	2.9	14
465	Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nature Reviews Cancer, 2018, 18, 148-167.	28.4	299
466	Atypical chronic lymphocytic leukemia presenting with massive IgM paraprotein. Annals of Hematology, 2018, 97, 921-922.	1.8	1
467	Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study. Annals of Hematology, 2018, 97, 475-484.	1.8	19
468	Extracellular vesicleâ€“mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling. Blood, 2018, 131, 1720-1729.	1.4	36
469	How I manage patients with cold agglutinin disease. British Journal of Haematology, 2018, 181, 320-330.	2.5	80
470	Ibrutinib discontinuation in WaldenstrÃ¶m macroglobulinemia: Etiologies, outcomes, and IgM rebound. American Journal of Hematology, 2018, 93, 511-517.	4.1	61
471	The 2016 revision of the WHO classification of lymphoid neoplasms: The clinician's view. Medicina ClÃ¡nica (English Edition), 2018, 150, 64-66.	0.2	3

#	Article	IF	Citations
472	Role of Brutonâ€™s tyrosine kinase in B cells and malignancies. Molecular Cancer, 2018, 17, 57.	19.2	435
473	Genetic convergence of rare lymphomas. Current Opinion in Hematology, 2018, 25, 307-314.	2.5	2
474	MYD88 L265P Mutation in Lymphoid Malignancies. Cancer Research, 2018, 78, 2457-2462.	0.9	92
475	Monoclonal Gammopathy of Undetermined Significance. , 2018, , 525-530.		0
476	MYD88 Mutations and Sensitivity to Ibrutinib Therapy. Journal of Molecular Diagnostics, 2018, 20, 264-266.	2.8	7
477	Highly sensitive MYD88 ^{L265P} mutation detection by droplet digital polymerase chain reaction in WaldenstrÃ¶m macroglobulinemia. Haematologica, 2018, 103, 1029-1037.	3.5	61
478	<scp>MYD</scp>88 mutations can be used to identify malignant pleural effusions in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2018, 180, 578-581.	2.5	19
479	Diagnosis and management of neuropathies associated with plasma cell dyscrasias. Hematological Oncology, 2018, 36, 3-14.	1.7	18
480	Overcoming multiple myeloma drug resistance in the era of cancer â€˜omicsâ€™. Leukemia and Lymphoma, 2018, 59, 542-561.	1.3	34
481	La revisiÃ³n de 2016 de la clasificaciÃ³n de la OMS de las neoplasias linfoides: la visiÃ³n del clÃnico. Medicina ClÃnica, 2018, 150, 64-66.	0.6	3
482	MYD88 mutation status does not impact overall survival in WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2018, 93, 187-194.	4.1	57
483	Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88L265P Mutation. Case Reports in Oncology, 2018, 10, 813-818.	0.7	4
484	Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement. Leukemia and Lymphoma, 2018, 59, 1256-1259.	1.3	7
485	Epigenetics and Epigenomics. , 2018, , 17-24.		2
486	Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leukemia and Lymphoma, 2018, 59, 1554-1564.	1.3	43
487	Recurrent gastrointestinal bleeding in a patient with IgM paraproteinaemia. Journal of Clinical Pathology, 2018, 71, 284-285.	2.0	1
488	<scp>MYD</scp>88 wildâ€type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, andÂoverall survival. British Journal of Haematology, 2018, 180, 374-380.	2.5	83
489	Comparing apples to oranges: A commentary on the <scp>M</scp>ayo study of <scp>MYD</scp>88 significance in <scp>W</scp>aldenstrom's macroglobulinemia.. American Journal of Hematology, 2018, 93, E69-E71.	4.1	1

#	Article	IF	Citations
490	The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid. Hematological Oncology, 2018, 36, 429-435.	1.7	86
491	The role of ibrutinib in WaldenstrÃ¶m macroglobulinemia. Expert Opinion on Orphan Drugs, 2018, 6, 85-89.	0.8	0
492	Intracapillary monoclonal deposits disease due to B-cell non-Hodgkin lymphoma: A case report and review of the literature. Journal of Onco-Nephrology, 2018, 2, 102-106.	0.6	1
493	IgG lymphoplasmacytic lymphoma: a case report. Annales De Biologie Clinique, 2018, 76, 665-668.	0.1	1
494	Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget, 2018, 9, 33416-33439.	1.8	107
495	Plasma Cell Neoplasms: an overview. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2018, , .	0.1	0
496	Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. Blood Advances, 2018, 2, 1985-1997.	5.2	39
497	Ibrutinib Monotherapy in Symptomatic, Treatment-NaÃ¯ve Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2018, 36, 2755-2761.	1.6	142
498	Molecular Hematopathology. , 2018, , 712-760.e18.		4
499	Multiple cystic lung lesions and autoimmune thrombocytopaenia developing after chemotherapy for pulmonary indolent B-cell lymphoma with plasmacytic differentiation. BMJ Case Reports, 2018, 11, e227548.	0.5	0
500	Definition of a minimal genes set for mature lymphoid blood diseases. Hematologie, 2018, 24, 27-59.	0.0	4
501	Intramolecular interaction suggests an autosuppression mechanism for the innate immune adaptor protein MyD88. Chemical Communications, 2018, 54, 12318-12321.	4.1	3
502	First-line ibrutinib for Bing-Neel syndrome. BMJ Case Reports, 2018, 2018, bcr-2018-226102.	0.5	6
503	Indolent B-cell lymphomas. , 2018, , .		0
505	Apport du sÃ©quenÃ§age haut dÃ©bit dans la prise en charge des hÃ©mopathies lymphoÃ¯des. Revue Francophone Des Laboratoires, 2018, 2018, 75-80.	0.0	0
506	Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment. Current Treatment Options in Oncology, 2018, 19, 71.	3.0	6
507	Pathological mutations differentially affect the self-assembly and polymerisation of the innate immune system signalling adaptor molecule MyD88. BMC Biology, 2018, 16, 149.	3.8	22
508	<scp>MYD</scp>88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in <scp>CLL</scp>. British Journal of Haematology, 2019, 184, 925-936.	2.5	18

#	Article	IF	Citations
509	WALDENSTROMâ€™S MACROGLOBULINEMIA: AN UPDATE. Mediterranean Journal of Hematology and Infectious Diseases, 2018, 10, e2018004.	1.3	21
510	Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms. Annals of Diagnostic Pathology, 2018, 37, 67-74.	1.3	19
511	MyD88 Regulates the Expression of SMAD4 and the Iron Regulatory Hormone Hepcidin. Frontiers in Cell and Developmental Biology, 2018, 6, 105.	3.7	7
512	A Case of Bingâ€“Neel Syndrome Successfully Treated with Ibrutinib. Case Reports in Hematology, 2018, 2018, 1-5.	0.4	12
513	WaldenstrÃ¶mâ€™s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv41-iv50.	1.2	63
514	Profiling of circulating exosomal miRNAs in patients with WaldenstrÃ¶m Macroglobulinemia. PLoS ONE, 2018, 13, e0204589.	2.5	17
516	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. Blood Cancer Journal, 2018, 8, 97.	6.2	36
517	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for WaldenstrÃ¶m macroglobulinemia. Nature Communications, 2018, 9, 4182.	12.8	15
518	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood, 2018, 132, 2608-2612.	1.4	29
519	Genetic Aspects of Hematopoietic Malignancies. , 2018, , 201-234.		1
520	Aberrant Activation of NF-Î²B Signalling in Aggressive Lymphoid Malignancies. Cells, 2018, 7, 189.	4.1	22
521	Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience. Blood Research, 2018, 53, 189.	1.3	10
522	Gene Expression Profile Signature of Aggressive WaldenstrÃ¶m Macroglobulinemia with Chromosome 6q Deletion. BioMed Research International, 2018, 2018, 1-8.	1.9	7
523	Thrombotic microangiopathy with intraglomerular IgM pseudothrombi in WaldenstrÃ¶m macroglobulinemia and IgM monoclonal gammopathy. Journal of Nephrology, 2018, 31, 907-918.	2.0	2
524	Effect of glutamine on lymphoplasmacytic lymphoma, especially on the viewpoint of the differentiation into vulnerable subpopulation. Pathology Research and Practice, 2018, 214, 1667-1674.	2.3	0
525	Microarray-Based Gene Expression Analysis Identifies Potential Diagnostic and Prognostic Biomarkers for WaldenstrÃ¶m Macroglobulinemia. Acta Haematologica, 2018, 140, 87-96.	1.4	2
526	Small B-Cell Lymphomas. , 2018, , 213-270.e3.		0
527	CBL-MZ is not a single biological entity: evidence from genomic analysis and prolonged clinical follow-up. Blood Advances, 2018, 2, 1116-1119.	5.2	6

#	Article	IF	Citations
528	A safety profile of medications used to treat WaldenstrÃ¶mâ€™s macroglobulinemia. Expert Opinion on Drug Safety, 2018, 17, 609-621.	2.4	2
529	Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkinâ€™s lymphoma. Expert Opinion on Emerging Drugs, 2018, 23, 111-122.	2.4	14
530	Phase 3 Trial of Ibrutinib plus Rituximab in WaldenstrÃ¶mâ€™s Macroglobulinemia. New England Journal of Medicine, 2018, 378, 2399-2410.	27.0	291
531	Defining Lymphoplasmacytic Lymphoma. American Journal of Clinical Pathology, 2018, 150, 168-176.	0.7	5
532	Activation of Toll-like receptors nucleates assembly of the MyDDosome signaling hub. ELife, 2018, 7, .	6.0	83
533	Initial Evaluation of the Patient with WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 811-820.	2.2	16
534	First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 853-864.	2.2	6
535	Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 745-752.	2.2	16
537	Working Toward a Genomic Prognostic Classification of WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 753-763.	2.2	5
538	The Bone Marrow Microenvironment in WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 777-786.	2.2	6
539	Familial WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 787-809.	2.2	13
540	WaldenstrÃ¶m Macroglobulinemia/Lymphoplasmacytic Lymphoma. , 2018, , 1419-1431.e5.		0
541	Diagnosis of Lymphoid Lesions in Limited Samples. American Journal of Clinical Pathology, 2018, 150, 471-484.	0.7	14
542	NF-Î²B Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy. Biomedicines, 2018, 6, 38.	3.2	37
543	Waldenstromâ€™s Macroglobulinemia. , 2018, , 617-638.		0
544	What Does This Mutation Mean? The Tools and Pitfalls of Variant Interpretation in Lymphoid Malignancies. International Journal of Molecular Sciences, 2018, 19, 1251.	4.1	11
545	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. Leukemia, 2018, 32, 2617-2625.	7.2	40
546	Potential Diagnosis of Vitreoretinal Lymphoma by Detection ofMYD88Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction. JAMA Ophthalmology, 2018, 136, 1098.	2.5	66

#	Article	IF	Citations
547	Novel Approaches in WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2018, 32, 875-890.	2.2	4
549	Idelalisib in a patient with refractory WaldenstrÃ¶mâ€™s macroglobulinemia complicated by anuric renal failure: a case report. Journal of Medical Case Reports, 2018, 12, 164.	0.8	2
550	Targeting Myddosome Signaling in WaldenstrÃ¶m's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clinical Cancer Research, 2018, 24, 6408-6420.	7.0	15
551	A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with WaldenstrÃ¶m macroglobulinemia. Future Oncology, 2018, 14, 2229-2237.	2.4	37
552	B-Cell Lymphocytosis. , 2018, , 329-381.		0
553	Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine, 2018, 109, 11-16.	3.2	70
554	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature, 2018, 560, 387-391.	27.8	276
555	Next generation sequencing in hematolymphoid neoplasia. Seminars in Hematology, 2019, 56, 2-6.	3.4	5
556	MYD88 and CXCR4 Mutation Profiling in Lymphoplasmacytic Lymphoma/Waldenstromâ€™s Macroglobulinaemia. Indian Journal of Hematology and Blood Transfusion, 2019, 35, 57-65.	0.6	5
558	Ibrutinib in the management of Waldenstrom macroglobulinemia. Journal of Oncology Pharmacy Practice, 2019, 25, 434-441.	0.9	4
559	MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 311-318.	1.2	12
560	Diagnosis of WaldenstrÃ¶m macroglobulinemia. Baylor University Medical Center Proceedings, 2019, 32, 394-396.	0.5	0
561	Rituximab and ibrutinib in the treatment of WaldenstrÃ¶mâ€™s macroglobulinemia. Future Oncology, 2019, 15, 2687-2697.	2.4	0
562	Role of Next Generation Sequencing (NGS) in Hematological Disorders. , 2019, , 491-502.		0
563	Update on Lymphoma classification: The 2016 revised World Health Organization Classification of Hematopoietic and Lymphoid Neoplasms. Advances in Cell and Gene Therapy, 2019, 2, e57.	0.9	3
564	Pathogenic Bâ€cell receptor signaling in lymphoid malignancies: New insights to improve treatment. Immunological Reviews, 2019, 291, 190-213.	6.0	91
566	CXCR4 mutations affect presentation and outcomes in patients with WaldenstrÃ¶m macroglobulinemia: A systematic review. Expert Review of Hematology, 2019, 12, 873-881.	2.2	29
567	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. American Journal of Hematology, 2019, 94, 1193-1199.	4.1	18

#	Article	IF	Citations
568	Single-cell MYD88 sequencing of isolated B cells from vitreous biopsies aids vitreoretinal lymphoma diagnosis. Blood, 2019, 134, 709-712.	1.4	15
569	How we manage Bingâ€“Neel syndrome. British Journal of Haematology, 2019, 187, 277-285.	2.5	45
570	Highâ€‘resolution melting analysis for rapid and sensitive MYD88 screening in chronic lymphocytic leukemia. Oncology Letters, 2019, 18, 814-821.	1.8	4
571	The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice. Frontiers in Oncology, 2019, 9, 528.	2.8	27
572	The MYD88^{L265P} conundrum in IgM monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2019, 187, 413-415.	2.5	2
573	Characteristics of WaldenstrÃ¶m Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e496-e505.	0.4	4
574	A riskâ€stratification model based on the initial concentration of the serum monoclonal protein and <scp>MYD</scp>88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to WaldenstrÃ¶m macroglobulinaemia or other lymphoproliferative disorders. British Journal of Haematology, 2019, 187, 441-446.	2.5	13
575	CXCR4 mutation subtypes impact response and survival outcomes in patients with WaldenstrÃ¶m macroglobulinaemia treated with ibrutinib. British Journal of Haematology, 2019, 187, 356-363.	2.5	73
576	Imaging of WaldenstrÃ¶m Macroglobulinemia: A Comprehensive Review for the Radiologist in the Era of Personalized Medicine. American Journal of Roentgenology, 2019, 213, W248-W256.	2.2	9
577	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms. American Journal of Clinical Pathology, 2019, 152, 277-301.	0.7	6
578	Simultaneous Presentation of WaldenstrÃ¶m's Macroglobulinemia and MYD88 Gene Mutation with Multiple Myeloma. Cureus, 2019, 11, e3822.	0.5	0
579	What is the most appropriate regimen for untreated WaldenstrÃ¶m macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness. Blood Research, 2019, 54, 153-156.	1.3	1
580	Exploratory Study of <scp>MYD</scp>88 L265P, Rare <scp>NLRP</scp>3 Variants, and Clonal Hematopoiesis Prevalence in Patients With Schnitzler Syndrome. Arthritis and Rheumatology, 2019, 71, 2121-2125.	5.6	33
581	Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma. Hematology/Oncology Clinics of North America, 2019, 33, 553-574.	2.2	2
582	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. Hematology/Oncology Clinics of North America, 2019, 33, 639-656.	2.2	12
583	Evaluating ibrutinib in the treatment of symptomatic Waldenstromâ€™s macroglobulinemia . Journal of Blood Medicine, 2019, Volume 10, 291-300.	1.7	13
584	Unclassifiable Isolated Monoclonal Lymphocytosis: Comprehensive Description of a Retrospective Cohort. Cancers, 2019, 11, 1495.	3.7	0
585	Clinical Relevance of the High Prevalence of MYD88 L265P Mutated Vitreoretinal Lymphoma Identified by Droplet Digital Polymerase Chain Reaction. Ocular Immunology and Inflammation, 2021, 29, 448-455.	1.8	16

#	Article	IF	Citations
587	MYD88 L265P mutation analysis is a useful diagnostic adjunct for lymphoplasmacytic lymphoma with pleural effusion. Pathology International, 2019, 69, 601-607.	1.3	5
591	Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of WaldenstrÃ¶mâ€™s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. PLoS ONE, 2019, 14, e0221941.	2.5	15
592	How I treat WaldenstrÃ¶m macroglobulinemia. Blood, 2019, 134, 2022-2035.	1.4	65
593	Follicular Lymphoma Presenting With Monoclonal IgM And MYD88 Mutation: A Case Report And Review Of The Literature . OncoTargets and Therapy, 2019, Volume 12, 7833-7842.	2.0	1
594	Disrupting myddosome assembly in diffuse large Bâ€˜cell lymphoma cells using the MYD88 dimerization inhibitor ST2825. Oncology Reports, 2019, 42, 1755-1766.	2.6	9
596	What is new in the treatment of Waldenstrom macroglobulinemia?. Leukemia, 2019, 33, 2555-2562.	7.2	19
598	Cryoglobulinemia as a Possible Primer for TRALI: Report of a Case. Laboratory Medicine, 2019, 50, 313-319.	1.2	1
599	Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptorâ€“associated kinase 4 (IRAK4). Journal of Biological Chemistry, 2019, 294, 4511-4519.	3.4	14
601	AL amyloidosis with a localized B cell neoplasia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 353-363.	2.8	15
602	High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals. Blood Cancer Journal, 2019, 9, 8.	6.2	27
603	Cold agglutinin disease: current challenges and future prospects . Journal of Blood Medicine, 2019, Volume 10, 93-103.	1.7	39
604	Schnitzlerâ€™s syndrome - a novel hypothesis of a shared pathophysiologic mechanism with WaldenstrÃ¶mâ€™s disease. Orphanet Journal of Rare Diseases, 2019, 14, 151.	2.7	15
605	Malabsorption and Malnutrition Disorders. , 2019, , 191-238.		1
606	Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Frontiers in Immunology, 2019, 10, 1121.	4.8	103
607	Germline Risk Contribution to Genomic Instability in Multiple Myeloma. Frontiers in Genetics, 2019, 10, 424.	2.3	10
608	Updates in prognostication and treatment of WaldenstrÃ¶mâ€™s macroglobulinemia. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 179-188.	0.9	8
609	T-Cell Deletion of MyD88 Connects IL17 and ÎºBÎ¶ to RAS Oncogenesis. Molecular Cancer Research, 2019, 17, 1759-1773.	3.4	9
610	Schnitzler syndrome. Hautarzt, 2019, , 1.	2.1	8

#	Article	IF	Citations
611	MYD88L265P mutated IgA lymphoplasmacytic lymphoma. Histopathology, 2019, 75, 608-612.	2.9	0
612	A revised international prognostic score system for WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia, 2019, 33, 2654-2661.	7.2	53
613	Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis . OncoTargets and Therapy, 2019, Volume 12, 2751-2766.	2.0	9
614	Schnitzler syndrome associated with MYD88 L265P mutation. JAAD Case Reports, 2019, 5, 312-316.	0.8	7
615	A 50-Year-Long Study of WaldenstrÃ¶m Macroglobulinemia. Mayo Clinic Proceedings, 2019, 94, 394-396.	3.0	1
616	⁶⁸Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in WaldenstrÃ¶m Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to ¹⁸F-FDG PET/CT. Journal of Nuclear Medicine, 2019, 60, 1724-1729.	5.0	37
617	Biology and therapy of multiple myeloma. Medical Journal of Australia, 2019, 210, 375-380.	1.7	78
618	Progression Risk Stratification of Asymptomatic WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2019, 37, 1403-1411.	1.6	65
619	Molecular diagnosis of lymphoma: a case-based practical approach. Diagnostic Histopathology, 2019, 25, 229-239.	0.4	1
620	The role of high serum CXCL13 level in WaldenstrÃ¶m macroglobulinemia. Leukemia Research, 2019, 81, 50-55.	0.8	1
621	A Recurrent Activating Missense Mutation in WaldenstrÃ¶m Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation. Cancer Discovery, 2019, 9, 796-811.	9.4	30
622	Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. Acta Neuropathologica Communications, 2019, 7, 43.	5.2	44
623	Molecular Diagnostics in Non-Hodgkin Lymphoma. , 2019, , 103-127.		0
625	Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells. Molecular Cancer Research, 2019, 17, 1365-1377.	3.4	13
626	Lymphome lymphoplasmocytaire Ã IgG avec amylose mÃ©dullaire. Revue Francophone Des Laboratoires, 2019, 2019, 60-62.	0.0	0
627	How Recent Advances in Biology of WaldenstrÃ¶mâ€™s Macroglobulinemia May Affect Therapy Strategy. Current Oncology Reports, 2019, 21, 27.	4.0	4
628	Origin and Pathogenesis of B Cell Lymphomas. Methods in Molecular Biology, 2019, 1956, 1-33.	0.9	26
629	Digital <scp>PCR</scp> in bone marrow trephine biopsies is highly sensitive for MYD88^{L265P} detection in lymphomas with plasmacytic/plasmacytoid differentiation. British Journal of Haematology, 2019, 186, 189-191.	2.5	7

#	Article	IF	Citations
630	IgA-producing lymphoplasmacytic lymphoma carrying the chromosomal abnormality t(8;14). Journal of Clinical and Experimental Hematopathology: JCEH, 2019, 59, 124-129.	0.8	1
631	A Case of Lymphoplasmacytic Lymphoma/WaldenstrÃ¶m's Macroglobulinemia with IgM-Îº and IgA-Î» Biclonal Gammopathy. Laboratory Medicine Online, 2019, 9, 263.	0.2	0
632	Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. Blood Advances, 2019, 3, 3360-3374.	5.2	25
633	CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2019, 3, 2800-2803.	5.2	27
634	Successful treatment of non-IgM lymphoplasmacytic lymphoma by bortezomib-containing regimen: case reports and review of literature. Blood Research, 2019, 54, 236-240.	1.3	2
635	Treatment options for relapsed WaldenstrÃ¶m's Macroglobulinemia. HemaSphere, 2019, 3, 65-67.	2.7	0
636	Application of Genomics to Clinical Practice in Haematological Malignancy. Current Genetic Medicine Reports, 2019, 7, 236-252.	1.9	0
637	Using genomic data for selecting the treatment of lymphoma patients. Current Opinion in Hematology, 2019, 26, 303-312.	2.5	2
638	Genomic landscape of WaldenstrÃ¶m's macroglobulinemia. HemaSphere, 2019, 3, 58-61.	2.7	1
639	MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA. Retina, 2019, 39, 679-684.	1.7	50
640	<scp>TP</scp>53 mutations are associated with mutated <scp>MYD</scp>88 and <scp>CXCR</scp>4, and confer an adverse outcome in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2019, 184, 242-245.	2.5	33
641	Diagnostic framing of IgM monoclonal gammopathy: Focus on WaldenstrÃ¶m macroglobulinemia. Hematological Oncology, 2019, 37, 117-128.	1.7	15
642	CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. British Journal of Haematology, 2019, 184, 625-633.	2.5	10
643	Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers, 2019, 11, 11.	3.7	46
644	Long survival in patients with WaldenstrÃ¶m macroglobulinaemia diagnosed at a young age. British Journal of Haematology, 2019, 185, 799-802.	2.5	4
645	IRTA1 and MNDA Expression in Marginal Zone Lymphoma. American Journal of Clinical Pathology, 2019, 151, 337-343.	0.7	31
646	Lymphomas. , 2019, , 1065-1077.e1.		0
647	WaldenstrÃ¶m macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2019, 94, 266-276.	4.1	68

#	Article	IF	Citations
648	High Frequency of MYD88 L265P Mutation in Primary Ocular Adnexal Marginal Zone Lymphoma and Its Clinicopathologic Correlation: A Study From a Single Institution. Archives of Pathology and Laboratory Medicine, 2019, 143, 483-493.	2.5	10
649	Predictive Biomarkers and Targeted Therapies for Lymphoid Malignancies. , 2019, , 363-374.		0
650	Taming the Heterogeneity of Aggressive Lymphomas for Precision Therapy. Annual Review of Cancer Biology, 2019, 3, 429-455.	4.5	18
651	Molecular Diagnostics in Cytopathology. , 2019, , .		0
652	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nature Reviews Nephrology, 2019, 15, 45-59.	9.6	330
653	TLR Signaling Is Activated in Lymph Nodeâ€“Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib. Cancer Research, 2019, 79, 360-371.	0.9	47
654	Molecular Diagnostics in Hematologic Malignancies. , 2019, , 405-424.		0
655	Understanding early TLR signaling through the Myddosome. Journal of Leukocyte Biology, 2019, 105, 339-351.	3.3	130
656	Gene Expression Profiling Reveals Aberrant T-cell Marker Expression on Tumor Cells of WaldenstrÃ¶m's Macroglobulinemia. Clinical Cancer Research, 2019, 25, 201-209.	7.0	9
657	Immunohistochemical and Immunocytochemical Analyses in Patients with Vitreoretinal Lymphoma. Ocular Immunology and Inflammation, 2020, 28, 147-155.	1.8	11
659	Navigating the cutaneous B-cell lymphomas: avoiding the rocky shoals. Modern Pathology, 2020, 33, 96-106.	5.5	16
661	Ibrutinib monotherapy outside of clinical trial setting in WaldenstrÃ¶m macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	2.5	41
662	Multiple Myeloma and Related Disorders. , 2020, , 1884-1910.e7.		4
663	Non-Hodgkin Lymphomas. , 2020, , 1926-1947.e5.		0
664	Bing-Neel syndrome presenting as isolated CNS lymphoplasmacytic lymphoma: A case report and review of the literature. Journal of Clinical Neuroscience, 2020, 71, 277-280.	1.5	5
665	Deepening of response after completing rituximabâ€containing therapy in patients with Waldenstrom macroglobulinemia. American Journal of Hematology, 2020, 95, 372-378.	4.1	6
666	Lymphoma 2020: an update on recent advances in pathobiology and application to clinical practice. Pathology, 2020, 52, 1-5.	0.6	3
667	Maculopathy in Patients with Monoclonal Gammopathy of Undetermined Significance. Ophthalmology Retina, 2020, 4, 300-309.	2.4	15

#	Article	IF	Citations
668	CRL3â€“SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-ÎºB signaling. Leukemia, 2020, 34, 1305-1314.	7.2	38
669	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	7.2	40
671	Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Reviews, 2020, 41, 100648.	5.7	267
672	Lymphoplasmacytic lymphoma and WaldenstrÃ¶m macroglobulinaemia: clinicopathological features and differential diagnosis. Pathology, 2020, 52, 6-14.	0.6	22
673	A practical guide to laboratory investigations at diagnosis and follow up in WaldenstrÃ¶m macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology, 2020, 52, 167-178.	0.6	23
674	Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice. Cancers, 2020, 12, 2913.	3.7	24
675	Comparative genomics of CXCR4MUT and CXCR4WT single cells in WaldenstrÃ¶mâ€™s macroglobulinemia. Blood Advances, 2020, 4, 4550-4553.	5.2	3
676	Routine next generation sequencing of lymphoid malignancies: clinical utility and challenges from a 3-Year practical experience. Leukemia and Lymphoma, 2020, 61, 2568-2583.	1.3	10
677	An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia. Expert Opinion on Pharmacotherapy, 2020, 21, 1555-1564.	1.8	2
678	Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With WaldenstrÃ¶m Macroglobulinemia on and off Clinical Trials. HemaSphere, 2020, 4, e363.	2.7	12
679	Light Chain Deposition Disease in a Patient With MYD88 L265P Mutation-positive Low-grade B-cell Lymphoma and Monoclonal Immunoglobulin G Îº. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e805-e808.	0.4	1
680	Method validation. , 2020, , 57-75.		0
681	Evidence of B Cell Clonality and Investigation Into Properties of the IgM in Patients With Schnitzler Syndrome. Frontiers in Immunology, 2020, 11, 569006.	4.8	6
682	Management of WaldenstrÃ¶m macroglobulinemia in 2020. Hematology American Society of Hematology Education Program, 2020, 2020, 372-379.	2.5	24
683	Zanubrutinib for the treatment of patients with WaldenstrÃ¶m macroglobulinemia: 3 years of follow-up. Blood, 2020, 136, 2027-2037.	1.4	78
684	A multicenter, openâ€label, phase II study of tirabrutinib (ONO/GSâ€4059) in patients with WaldenstrÃ¶mâ€™s macroglobulinemia. Cancer Science, 2020, 111, 3327-3337.	3.9	60
685	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic WaldenstrÃ¶m macroglobulinemia: the ASPEN study. Blood, 2020, 136, 2038-2050.	1.4	281
686	What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics. Blood, 2020, 136, 1623-1631.	1.4	23

#	Article	IF	Citations
687	Targeted nextâ€generation sequencing reveals molecular heterogeneity in nonâ€chronic lymphocytic leukemia clonal Bâ€cell lymphocytosis. Hematological Oncology, 2020, 38, 689-697.	1.7	7
688	Complete Response of a Young Woman With MYD88WT Bing-Neel Syndrome on Ibrutinib Monotherapy Following a Single Cycle of B Hyper-CVAD/IT MTX. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e809-e812.	0.4	0
689	Type 1 cryoglobulinemic neuropathy associated with lymphoplasmacytic lymphoma. Acta Neurologica Belgica, 2021, 121, 1887-1890.	1.1	0
690	Ixazomib, dexamethasone, and rituximab in treatment-naive patients with WaldenstrÃ¶m macroglobulinemia: long-term follow-up. Blood Advances, 2020, 4, 3952-3959.	5.2	35
691	Lymphoplasmacytic lymphoma in a patient with Birtâ€“Haggâ€“DubÃ© syndrome. International Journal of Hematology, 2020, 112, 864-870.	1.6	2
692	Emerging drugs for the treatment of WaldenstrÃ¶m macroglobulinemia. Expert Opinion on Emerging Drugs, 2020, 25, 433-444.	2.4	3
693	Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer Journal, 2020, 10, 86.	6.2	10
694	Myeloid Differentiation Primary Response Protein 88 (MyD88): The Central Hub of TLR/IL-1R Signaling. Journal of Medicinal Chemistry, 2020, 63, 13316-13329.	6.4	52
695	Primary Central Nervous System Lymphomas: A Diagnostic Overview of Key Histomorphologic, Immunophenotypic, and Genetic Features. Diagnostics, 2020, 10, 1076.	2.6	22
696	B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS. Frontiers in Immunology, 2020, 11, 602868.	4.8	7
697	Role of Specific B-Cell Receptor Antigens in Lymphomagenesis. Frontiers in Oncology, 2020, 10, 604685.	2.8	11
698	Zanubrutinib for the treatment of WaldenstrÃ¶m Macroglobulinemia. Expert Review of Hematology, 2020, 13, 1303-1310.	2.2	3
699	Zanubrutinib for the treatment of MYD88 wild-type WaldenstrÃ¶m macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Advances, 2020, 4, 6009-6018.	5.2	57
701	The race to stymie BTK: zanu zings. Blood, 2020, 136, 1997-1999.	1.4	7
702	Essential Thrombocythaemia with Concomitant WaldenstrÃ¶m Macroglobulinaemia: Case Report and Literature Review . OncoTargets and Therapy, 2020, Volume 13, 3431-3435.	2.0	0
703	Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies. International Journal of Molecular Sciences, 2020, 21, 3141.	4.1	35
704	Untangling the Epigenetic Imbalance in B cell Lymphoma. Current Pharmacology Reports, 2020, 6, 110-120.	3.0	1
705	LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells. Blood, 2020, 136, 684-697.	1.4	32

#	Article	IF	Citations
706	Identification of two DNA methylation subtypes of WaldenstrÃ¶m's macroglobulinemia with plasma and memory B cell features. Blood, 2020, 136, 585-595.	1.4	10
707	The BLIMP1â€"EZH2 nexus in a non-Hodgkin lymphoma. Oncogene, 2020, 39, 5138-5151.	5.9	3
708	A Chinese case series of Schnitzler syndrome and complete remission in one tocilizumab-treated patient. Clinical Rheumatology, 2020, 39, 3847-3852.	2.2	13
709	Scientific Advances and the Evolution of Diagnosis, Subclassification and Treatment of Lymphoma. Archives of Medical Research, 2020, 51, 749-764.	3.3	5
710	Molecular Diagnostics of Non-Hodgkin Lymphoma. Cancer Journal (Sudbury, Mass), 2020, 26, 186-194.	2.0	3
711	Lymphoma Classification. Cancer Journal (Sudbury, Mass), 2020, 26, 176-185.	2.0	68
712	Detection of the MYD88L265P and CXCR4S338X mutations by cell-free DNA in WaldenstrÃ¶m macroglobulinemia. Annals of Hematology, 2020, 99, 1763-1769.	1.8	11
713	Immunoglobulin M Paraproteinaemias. Cancers, 2020, 12, 1688.	3.7	15
714	TLR-mediated activation of WaldenstrÃ¶m macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation. Blood Advances, 2020, 4, 2821-2836.	5.2	5
715	The current role of BTK inhibitors in the treatment of Waldenstromâ€™s Macroglobulinemia. Expert Review of Anticancer Therapy, 2020, 20, 663-674.	2.4	4
716	Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/WaldenstrÃ¶m macroglobulinaemia and description of its mutational profiles by targeted NGS. Journal of Clinical Pathology, 2020, 73, 571-577.	2.0	7
717	Association of small-fiber polyneuropathy with three previously unassociated rare missense SCN9A variants. Canadian Journal of Pain, 2020, 4, 19-29.	1.7	7
718	Droplet Digital PCR Assay for MYD88^{L265P}: Clinical Applications in WaldenstrÃ¶m Macroglobulinemia. HemaSphere, 2020, 4, e324.	2.7	3
719	Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia and Its Impact on Treatment Strategies. Journal of Clinical Oncology, 2020, 38, 1198-1208.	1.6	103
720	Genomic evolution of ibrutinibâ€resistant clones in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2020, 189, 1165-1170.	2.5	23
721	<scp>CXCR4</scp> mutational status does not impact outcomes in patients with <scp>W</scp>aldenstrÃ¶m macroglobulinemia treated with proteasome inhibitors. American Journal of Hematology, 2020, 95, E95-E98.	4.1	12
722	MyD88 Death-Domain Oligomerization Determines Myddosome Architecture: Implications for Toll-like Receptor Signaling. Structure, 2020, 28, 281-289.e3.	3.3	45
723	Waldenstrom's macroglobulinemia in the era of immunotherapy. Leukemia and Lymphoma, 2020, 61, 1292-1304.	1.3	1

#	Article	IF	Citations
724	Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer. Cancer Immunology, Immunotherapy, 2020, 69, 315-324.	4.2	12
725	Novel Treatment Strategies in the Management of WaldenstrÃ¶m Macroglobulinemia. Current Hematologic Malignancy Reports, 2020, 15, 31-43.	2.3	9
726	Lymphoplasmacytic lymphoma infiltrating both lacrimal glands in a patient with WaldenstrÃ¶m's macroglobulinemia. American Journal of Ophthalmology Case Reports, 2020, 17, 100597.	0.7	4
727	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 1388-1394.	1.3	9
728	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer Journal, 2020, 10, 12.	6.2	34
729	Hematopathology. , 2020, , 1729-2141.		0
730	Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma. Journal of Virology, 2020, 94, .	3.4	10
731	Composite monoclonal Bâ€cell lymphocytosis and MYD88 L265Pâ€positive lymphoplasmacytic lymphoma in a patient with IgM light chain amyloidosis: Case report. Pathology International, 2020, 70, 458-462.	1.3	2
732	An unusual case of cutaneous WaldenstrÃ¶m macroglobulinemia with the <scp>MYD88 L265P</scp> mutation. Journal of Cutaneous Pathology, 2020, 47, 850-853.	1.3	3
733	Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. Blood Advances, 2020, 4, 141-153.	5.2	13
734	New Insights on the Emerging Genomic Landscape of CXCR4 in Cancer: A Lesson from WHIM. Vaccines, 2020, 8, 164.	4.4	9
735	Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2020, 60, 124-129.	0.8	8
736	Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. Haematologica, 2021, 106, 1120-1128.	3.5	37
737	Non-Hodgkin Lymphomas: Malignancies Arising from Mature B Cells. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a034843.	6.2	3
738	6q deletion in WaldenstrÃ¶m macroglobulinaemia negatively affects time to transformation and survival. British Journal of Haematology, 2021, 192, 843-852.	2.5	28
739	MYD88 L265P elicits mutation-specific ubiquitination to drive NF-ÎºB activation and lymphomagenesis. Blood, 2021, 137, 1615-1627.	1.4	21
740	WaldenstrÃ¶m Macroglobulinemia: Clinico-pathological Profile and Treatment Outcomes of Patients from a Tertiary Care Centre of North India. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 386-390.	0.6	0
741	Halting the FGF/FGFR axis leads to antitumor activity in WaldenstrÃ¶m macroglobulinemia by silencing MYD88. Blood, 2021, 137, 2495-2508.	1.4	4

#	Article	IF	Citations
742	Partial response or better at sixÂmonths is prognostic of superior progressionâ€free survival in WaldenstrÃ¶m macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology, 2021, 192, 542-550.	2.5	8
743	Synthetic lethality between MyD88 loss and mutations in Wnt/Î²-catenin pathway in intestinal tumor epithelial cells. Oncogene, 2021, 40, 408-420.	5.9	11
744	CXCR4 in WaldenstrÃ¶mâ€™s Macroglobulinema: chances and challenges. Leukemia, 2021, 35, 333-345.	7.2	53
745	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice. Modern Pathology, 2021, 34, 904-921.	5.5	11
746	Case 6-2021: A 65-Year-Old Man with Eye Pain and Decreased Vision. New England Journal of Medicine, 2021, 384, 745-753.	27.0	2
747	Monoclonal gammopathy of undetermined significance (MGUS): where is the hidden danger? Definition and work-up. Memo - Magazine of European Medical Oncology, 2021, 14, 76-79.	0.5	1
748	Current and Emerging Treatments for WaldenstrÃ¶m Macroglobulinemia. Acta Haematologica, 2021, 144, 146-157.	1.4	7
749	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2021, 39, 565-575.	1.6	98
750	Current and novel BTK inhibitors in WaldenstrÃ¶mâ€™s macroglobulinemia. Therapeutic Advances in Hematology, 2021, 12, 204062072198958.	2.5	11
751	Waldenstromâ€™s Macroglobulinemia. Hematologic Malignancies, 2021, , 143-161.	0.2	3
752	Molecular Genetics in Indolent Lymphomas. Hematologic Malignancies, 2021, , 5-20.	0.2	0
753	Indolent and Aggressive B-Cell Lymphoma. , 2021, , 217-250.		0
754	Epigenetic targeting of WaldenstrÃ¶m macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition. Epigenomics, 2021, 13, 129-144.	2.1	7
755	An unusual case of lymphoplasmacytic lymphoma/WaldenstrÃ¶m macroglobulinemia presenting with intractable seizures and interference with automated testing. Journal of Hematopathology, 2021, 14, 69-73.	0.4	1
756	Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of WaldenstrÃ¶m macroglobulinemia. Cytometry Part B - Clinical Cytometry, 2021, , .	1.5	3
757	Significance of abnormal 53BP1 expression as a novel molecular pathologic parameter of follicular-shaped B-cell lymphoid lesions in human digestive tract. Scientific Reports, 2021, 11, 3074.	3.3	3
758	Applications of next-generation sequencing in hematologic malignancies. Human Immunology, 2021, 82, 859-870.	2.4	8
759	MYD88 signals induce tumour-initiating cell generation through the NF-ÎºB-HIF-1Î± activation cascade. Scientific Reports, 2021, 11, 3991.	3.3	8

#	Article	IF	Citations
760	Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in WaldenstrÃ¶mâ€™s Macroglobulinemia. Cancers, 2021, 13, 826.	3.7	15
761	A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia. Turkish Journal of Haematology, 2021, 38, 87-89.	0.5	2
762	A MyD88/IL1R Axis Regulates PD-1 Expression on Tumor-Associated Macrophages and Sustains Their Immunosuppressive Function in Melanoma. Cancer Research, 2021, 81, 2358-2372.	0.9	16
763	Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clinical Activity and Promising Future Directions. Journal of Clinical Oncology, 2021, 39, 548-550.	1.6	1
764	Light chain proteinuria revealing mu-heavy chain disease: an atypical presentation of WaldenstrÃ¶m macroglobulinemia in two cases. Haematologica, 2021, 106, 2034-2036.	3.5	1
765	Clinical application of genomics in WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2021, 62, 1805-1815.	1.3	3
766	Clinical Utility of Targeted Next-Generation Sequencing in the Evaluation of Low-Grade Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2021, 156, 433-444.	0.7	5
767	B-cell neoplasms and Hodgkin lymphoma in the spleen. Seminars in Diagnostic Pathology, 2021, 38, 125-134.	1.5	3
768	Reducing treatment toxicity in WaldenstrÃ¶m macroglobulinemia. Expert Opinion on Drug Safety, 2021, 20, 1-8.	2.4	2
769	Screening and identification of a novel FHL2 mutation by whole exome sequencing in twins with familial WaldenstrÃ¶m macroglobulinemia. Cancer, 2021, 127, 2039-2048.	4.1	2
770	How I treat cold agglutinin disease. Blood, 2021, 137, 1295-1303.	1.4	63
771	A case report of lymphoplasmacytic lymphoma with paraprotein IgA and IgM. Medicine, Case Reports and Study Protocols, 2021, 2, e0045.	0.1	1
772	Time to Move to the Single-Cell Level: Applications of Single-Cell Multi-Omics to Hematological Malignancies and WaldenstrÃ¶mâ€™s Macroglobulinemiaâ€”A Particularly Heterogeneous Lymphoma. Cancers, 2021, 13, 1541.	3.7	8
773	Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2. Diagnostics, 2021, 11, 600.	2.6	3
774	VS38 staining contributes to a novel gating strategy in flow cytometry for small B cell lymphoma, especially in lymphoplasmacytic lymphoma/WaldenstrÃ¶m macroglobulinemia. Cytometry Part B - Clinical Cytometry, 2021, , .	1.5	0
775	Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic nextâ€generation sequencing in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 194, 730-733.	2.5	16
776	IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis. Blood Advances, 2021, 5, 2101-2105.	5.2	7
777	MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation. Diagnostics, 2021, 11, 779.	2.6	14

#	Article	IF	Citations
778	Genetic Predictors of Mortality in Patients with Multiple Myeloma. The Application of Clinical Genetics, 2021, Volume 14, 241-254.	3.0	6
779	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for WaldenstrÃ¶m macroglobulinemia. Neoplasia, 2021, 23, 361-374.	5.3	16
780	Initial Experience Treating HPV-Related Laryngeal Diseases with Oral Brincidofovir: A Pilot Study. Annals of Otology, Rhinology and Laryngology, 2021, 130, 000348942110072.	1.1	0
781	Cellâ€free <scp>DNA</scp> analysis for detection of <scp>MYD88^{L265P}</scp> and <scp>CXCR4^{S338X}</scp> mutations in <scp>W</scp>aldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2021, 96, E250-E253.	4.1	8
782	Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with WaldenstrÃ¶m macroglobulinemia/lymphoplasmacytic lymphoma. International Journal of Hematology, 2021, 114, 401-407.	1.6	3
783	Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2021, 5, 2438-2446.	5.2	20
784	Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism. Redox Biology, 2021, 41, 101927.	9.0	4
785	Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells. Frontiers in Immunology, 2021, 12, 641692.	4.8	11
786	Real-world data on the survival outcome of patients with newly diagnosed WaldenstrÃ¶m macroglobulinemia. Korean Journal of Internal Medicine, 2021, 36, 668-678.	1.7	2
787	Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma. EJHaem, 2021, 2, 565-568.	1.0	0
788	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood, 2021, 138, 1966-1979.	1.4	16
789	Chemokine Receptor 4â€“Targeted 68Ga-Pentixafor PET/CT in Response Assessment of WaldenstrÃ¶m Macroglobulinemia/Lymphoplasmacytic Lymphoma. Clinical Nuclear Medicine, 2021, 46, 732-737.	1.3	9
790	Resistance Mutations to BTK Inhibitors Originate From the NF-ÎºB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. Frontiers in Immunology, 2021, 12, 689472.	4.8	32
791	Absence of Non-Canonical, Inhibitory MYD88 Splice Variants in B Cell Lymphomas Correlates With Sustained NF-ÎºB Signaling. Frontiers in Immunology, 2021, 12, 616451.	4.8	8
792	Managing complications secondary to WaldenstrÃ¶mâ€™s macroglobulinemia. Expert Review of Hematology, 2021, 14, 1-12.	2.2	0
793	Natural history of WaldenstrÃ¶m macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica, 2022, 107, 1163-1171.	3.5	11
794	The Spectrum of Ocular Manifestations in Patients with WaldenstrÃ¶mâ€™s Macroglobulinemia. Ocular Immunology and Inflammation, 2021, , 1-10.	1.8	5
795	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated WaldenstrÃ¶m macroglobulinemia. Blood, 2021, 138, 1535-1539.	1.4	32

#	Article	IF	Citations
796	Endomyocardial biopsy with co-localization of a lymphoplasmacytic lymphoma and AL amyloidosis. Cardiovascular Pathology, 2021, 53, 107348.	1.6	5
797	Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in WaldenstrÃ¶m Macroglobulinemia. HemaSphere, 2021, 5, e624.	2.7	15
798	Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors. Frontiers in Immunology, 2021, 12, 694853.	4.8	30
799	A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2021, 27, 5492-5501.	7.0	19
800	mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ TÂcell response. Molecular Therapy, 2021, 29, 2227-2238.	8.2	42
801	WaldenstrÃ¶mâ€™s Macroglobulinemia: An Exploration into the Pathology and Diagnosis of a Complex B-Cell Malignancy. Journal of Blood Medicine, 2021, Volume 12, 795-807.	1.7	7
802	Ibrutinib plus rituximab for the treatment of adult patients with WaldenstrÃ¶mâ€™s macroglobulinemia: a safety evaluation. Expert Opinion on Drug Safety, 2021, 20, 987-995.	2.4	4
803	How to Sequence Therapies in WaldenstrÃ¶m Macroglobulinemia. Current Treatment Options in Oncology, 2021, 22, 92.	3.0	5
804	Disease outcomes and biomarkers of progression in smouldering WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	2.5	12
805	IgM Plasma Cell Myeloma. American Journal of Clinical Pathology, 2021, , .	0.7	5
806	Monoclonal B-cell Lymphocytosis Exacerbated by Prednisolone Therapy for Dermatomyositis. Internal Medicine, 2021, 60, 2853-2858.	0.7	2
807	How I manage autoimmune cytopenias in patients with lymphoid cancer. Blood, 2022, 139, 1479-1488.	1.4	3
808	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood Cancer Discovery, 2021, 2, 600-615.	5.0	15
809	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia, 2022, 36, 532-539.	7.2	50
810	Anti-MAG neuropathy: From biology to clinical management. Journal of Neuroimmunology, 2021, 361, 577725.	2.3	27
811	Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?. Blood Cells, Molecules, and Diseases, 2021, 91, 102595.	1.4	2
812	Lymph Nodes. , 2022, , 763-813.		0
814	Light Chain Cast Nephropathy in an African-American Woman with WaldenstrÃ¶mâ€™s Macroglobulinemia. American Journal of Medical Case Reports, 2021, 9, 167-169.	0.2	0

#	Article	IF	Citations
815	Analysis of the MYD88 L265P mutation in IgM monoclonal gammopathy by semi-nested polymerase chain reaction-based restriction fragment length polymorphism method. The Showa University Journal of Medical Sciences, 2021, 33, 47-54.	0.1	0
816	Unexpected discovery of prostatic diffuse large B-cell lymphoma after thulium laser vaporization in a patient with Waldenstrom macroglobulinemia. Quantitative Imaging in Medicine and Surgery, 2021, 12, 0-0.	2.0	1
817	Signaling Through Nucleic Acid Sensors and Their Roles in Inflammatory Diseases. Frontiers in Immunology, 2020, 11, 625833.	4.8	58
818	WaldenstrÃ¶m macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2021, 96, 258-269.	4.1	49
819	Mature B-Cell Neoplasms. , 2021, , 339-359.		0
823	Impact of Genetics on Mature Lymphoid Leukemias and Lymphomas. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a035444.	6.2	1
824	Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. JCI Insight, 2017, 2, e90196.	5.0	34
825	Whole-exome sequencing uncovers oxidoreductases DHTKD1 and OGDHL as linkers between mitochondrial dysfunction and eosinophilic esophagitis. JCI Insight, 2018, 3, .	5.0	39
826	Kaposi sarcomaâ€“associated herpesvirus: immunobiology, oncogenesis, and therapy. Journal of Clinical Investigation, 2016, 126, 3165-3175.	8.2	165
827	Bing-Neel syndrome: A case reports. Journal of Oncology Pharmacy Practice, 2021, 27, 1758-1761.	0.9	2
828	What should be the goal of therapy for WaldenstrÃ¶m macroglobulinemia patients? Complete response should be the goal of therapy. Blood Advances, 2017, 1, 2486-2490.	5.2	5
829	Insights into the genomic landscape of MYD88 wild-type WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2018, 2, 2937-2946.	5.2	72
830	Inherited Polymorphisms in Hyaluronan Synthase 1 Predict Risk of Systemic B-Cell Malignancies but Not of Breast Cancer. PLoS ONE, 2014, 9, e100691.	2.5	7
831	Rare Circulating Cells in Familial WaldenstrÃ¶m Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization. PLoS ONE, 2015, 10, e0136505.	2.5	6
832	The CXCL12/CXCR4 Signaling Pathway: A New Susceptibility Factor in Human Papillomavirus Pathogenesis. PLoS Pathogens, 2016, 12, e1006039.	4.7	34
833	Recurrent mutations in NF-Î°B pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas. Oncotarget, 2016, 7, 62627-62639.	1.8	52
834	Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors. Oncotarget, 2016, 7, 83294-83307.	1.8	38
835	The importance of the genomic landscape in WaldenstrÃ¶m's Macroglobulinemia for targeted therapeutical interventions. Oncotarget, 2017, 8, 35435-35444.	1.8	4

#	Article	IF	Citations
836	STAT3 mutation impacts biological and clinical features of T-LGL leukemia. Oncotarget, 2017, 8, 61876-61889.	1.8	67
837	Role of IRF4 in resistance to immunomodulatory (IMid) compoundsÂ® in WaldenstrÃ¶mâ€™s macroglobulinemia. Oncotarget, 2017, 8, 112917-112927.	1.8	5
838	How I treat rituximab refractory patients with WM. Oncotarget, 2018, 9, 36824-36825.	1.8	6
839	Bruton's tyrosine kinase: oncotarget in myeloma. Oncotarget, 2012, 3, 913-914.	1.8	26
840	Lymphoplasmacytic Lymphoma Presenting with Diarrhea and Joint Pain Which was Successfully Diagnosed by an MYD88 Mutation Analysis. Internal Medicine, 2017, 56, 847-851.	0.7	4
841	MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells. Anticancer Research, 2017, 37, 6203-6209.	1.1	22
842	Cutaneous Involvement in WaldenstrÃ¶mâ€™s Macroglobulinaemia. Acta Dermato-Venereologica, 2020, 100, adv00225.	1.3	7
843	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2018/2019. Acta Haematologica Polonica, 2018, 49, 157-206.	0.3	4
844	A prognostic index predicting survival in transformed WaldenstrÃ¶m macroglobulinemia. Haematologica, 2021, 106, 2940-2946.	3.5	11
845	Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR. Molecular Medicine Reports, 2020, 22, 1243-1256.	2.4	7
846	Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing. Oncology Letters, 2020, 20, 1-1.	1.8	3
847	Diagnostic significance and prognostic role of the ARID1A gene in cancer outcomes (Review). World Academy of Sciences Journal, 0, , .	0.6	9
848	MYD88 L265P mutation in intraocular lymphoma: A potential diagnostic marker. Indian Journal of Ophthalmology, 2020, 68, 2160.	1.1	13
849	BRAFV600E mutation in hairy cell leukemia: A single-center experience. Indian Journal of Pathology and Microbiology, 2018, 61, 532.	0.2	2
850	Precision diagnostics in lymphomas â€“ Recent developments and future directions. Seminars in Cancer Biology, 2022, 84, 170-183.	9.6	13
851	Successful treatment with tirabrutinib for relapsed lymphoplasmacytic lymphoma complicated by Bingâ€“Neel syndrome. International Journal of Hematology, 2022, 115, 585-589.	1.6	9
852	Indolente (niedrig maligne) Non-Hodgkin-Lymphome. , 2012, , 403-445.		0
853	Where Do We Stand in the Genomics of Lymphomas?. , 2013, , 495-541.		0

#	Article	IF	Citations
855	WaldenstrÃ¶mâ€™s Macroglobulinemia. , 2014, , 289-300.		1
856	Molecular Diagnostics of Lymphoid Neoplasms. , 2014, , 521-555.		1
858	Clonotypic Analysis Of Immunoglobulin Heavy Chain (IgH) Sequences In Patients With WaldenstrÃ¶mâ€™s Macroglobulinemia. Correlation With MYD88 L265P Somatic Mutation Status, Clinical Features and Outcome. Blood, 2013, 122, 1890-1890.	1.4	0
859	Transitioning Diagnostic Molecular Pathology to the Genomic Era: Cancer Somatic Mutation Panel Testing. , 2014, , 3-13.		0
860	AIDS-Related Primary Central Nervous System Lymphoma. , 2014, , 207-222.		0
861	Molecular Testing in Hematologic Malignancies. , 2014, , 135-167.		1
863	WaldenstrÃ¶mâ€™s Macroglobulinemia. , 2014, , 303-329.		0
864	A Diagnostic Approach to Patients with an IgM Monoclonal Protein. , 2014, 11, .		0
865	Signaling Pathways in Rare Lymphomas. , 2014, , 71-95.		0
866	Primary Malignant Lymphoma of Prostate with Silent <i>MYD</i>88 Mutation. Case Reports in Clinical Medicine, 2014, 03, 125-128.	0.2	0
867	Indolent Lymphomas: Follicular Lymphoma, HVC-Associated Marginal Zone B-Cell Lymphoma, and Waldenstromâ€™s Macroglobulinemia. , 2015, , 245-252.		0
868	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
871	The Role of PI3K/AKT/mTOR Inhibitors in the Treatment of Hematological Malignancies. , 2016, , 139-160.		0
872	B-Cell Non-Hodgkinâ€™s Lymphomas with Lymphoplasmacytoid and Plasmacytic Features. , 2016, , 1-22.		0
873	HIV and Indolent Lymphoma. , 2016, , 107-117.		0
874	MYD88 Mutation. , 2016, , 3-56-3-57.		0
875	Lymphoplasmacytic Lymphoma. , 2016, , 6-40-6-45.		0
876	B-Cell Malignancies. , 2016, , 579-602.		3

#	Article	IF	Citations
877	Risk Stratification in WaldenstrÃ¶m Macroglobulinemia. , 2017, , 279-293.		0
878	B-Cell Non-Hodgkinâ€™s Lymphomas with Lymphoplasmacytoid and Plasmacytic Features. , 2017, , 1637-1658.		0
879	Hematopoietic Proliferations. , 2017, , 461-479.		0
880	Indolente (niedrig maligne) Non-Hodgkin-Lymphome. , 2017, , 437-484.		0
881	Maligne aandoeningen van het lymfatische systeem. , 2017, , 601-621.		0
882	Lymphoplasmacytic lymphoma in the era of next generation sequencing. , 2017, , 97-109.		0
883	Bing-Neel Syndrome with Detectable MYD88 L265P Gene Mutation as a Late Relapse Following Autologous Hematopoietic Stem Cell Transplantation for WaldenstrÃ¶mâ€™s Macroglobulinemia. Turkish Journal of Haematology, 2017, 34, 186-187.	0.5	4
884	Hyperviscosity Syndrome Provoking Heart Failure in a Patient with WaldenstrÃ¶m macroglobinemia. MOJ Clinical & Medical Case Reports, 2017, 6, .	0.0	0
885	6. Diagnosis and Treatment of WaldenstrÃ¶m's Macroglobulinemia. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1948-1953.	0.0	0
886	Ibrutinib for rituximab-refractory WaldenstrÃ¶m macro-globulinemia. Oncotarget, 2018, 9, 12536-12537.	1.8	1
887	Lymphoplasmacytic Lymphoma. , 2018, , 792-797.		0
888	Gamma Heavy Chain Disease. , 2018, , 798-801.		0
889	Lymphoplasmacytic Lymphoma. Encyclopedia of Pathology, 2018, , 1-10.	0.0	0
890	Low-Grade Lymphomas (Other than CLL/SLL) in Older Patients. , 2018, , 1-15.		0
891	Bone Marrow Lymphoma. , 2018, , 77-102.		0
892	Tyrosine Kinases, microRNAs, Epigenetics: New Insights in the Mechanisms of Leukemogenesis. , 2018, , 11-25.		0
894	Indolente und kleinzellige B-Zell Lymphome. , 2019, , 523-600.		0
895	Lymphatische Neoplasien und ihre Manifestation im Knochenmark. , 2019, , 141-176.		0

#	Article	IF	Citations
896	Plasmazellneoplasien. , 2019, , 177-193.		0
897	A Case of Bing-Neel Syndrome Presenting as Vision Impairment and Numbness. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 2154-2161.	0.0	0
898	Understanding Molecular Testing in Patients Affected by Hematologic Disorders. , 2019, , 299-312.		0
899	Significance of oncogenic MYD88 and CD79B mutations in B-cell lymphomas. Tenri Medical Bulletin, 2018, 21, 81-89.	0.1	1
900	Waldenstrom macroglobulinemia presenting as plasma cell leukemia associated with hyperviscosity syndrome. Medical Science and Discovery, 0, , 390-392.	0.1	0
901	Resistance to Brutonâ€™s Tyrosine Kinase Signaling Pathway Targeted Therapies. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 111-153.	0.1	1
902	Current Therapeutic Options in WaldenstrÃ¶m Macroglobulinemia. Oncology & Hematology Review, 2019, 15, 39.	0.2	0
904	A 69-year-old woman with double vision and lower-extremity weakness. Cleveland Clinic Journal of Medicine, 2019, 86, 374-379.	1.3	0
905	Atypical clinical picture of waldenstrÃ¶mâ€™s macroglobulinemia: a difficult path to diagnosis. Klinicist, 2019, 13, 80-85.	0.5	0
906	Lymphomas. , 2020, , 253-315.		0
907	Lymphoplasmacytic Lymphoma. Encyclopedia of Pathology, 2020, , 315-324.	0.0	0
908	Lymph Nodes and Spleen. , 2020, , 65-100.		0
909	Severe Nephritis as Initial Sign of WaldenstrÃ¶mâ€™s Macroglobulinemia. Clinics and Practice, 2019, 9, 127-132.	1.4	0
910	Lymphoplasmacytic lymphoma with the MYD88^{L265P} mutation, producing non-IgM monoclonal immunoglobulins: 4 case reports. Tenri Medical Bulletin, 2019, 22, 12-28.	0.1	0
911	Nodal Malignant Lymphoma (With Comments on Extranodal Malignant Lymphoma and Metastatic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		0
913	Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of WaldenstrÃ¶m macroglobulinemia/lymphoplasmacytic lymphoma. EJNMMI Research, 2021, 11, 110.	2.5	3
914	A Rare Case of Synchronous WaldenstrÃ¶mâ€™s Macroglobulinemia and Cutaneous Squamous Cell Carcinoma with a Lung Mass: A Diagnostic and Management Dilemma. Case Reports in Oncology, 2021, 13, 1474-1482.	0.7	0
915	Low-Grade Lymphomas (Other than CLL/SLL) in Older Patients. , 2020, , 567-581.		0

#	Article	IF	Citations
916	Novel Therapeutics in theÂManagement of WaldenstrÃ¶m Macroglobulinemia. , 2020, , 15-26.		0
917	Composite Lymphoma. , 2020, , 323-344.		0
918	Lymphoplasmacytic lymphoma involving the mediastinum and the lung, followed by amyloidosis: A surgically and genetically proven case. Respiratory Medicine Case Reports, 2020, 31, 101313.	0.4	1
919	Bone Marrow Involvement by Lymphoid Neoplasms. , 2020, , 615-635.		0
920	Small B-Cell Lymphomas With and Without Plasmacytic Differentiation. , 2020, , 87-121.		0
921	Maligne aandoeningen van het lymfatische systeem. , 2020, , 615-641.		0
922	IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies. Current Opinion in Hematology, 2022, 29, 8-19.	2.5	42
923	Primary Isolated Lymphoplasmacytic Lymphoma (LPL) of the Stomach: A Case Report. American Journal of Case Reports, 2020, 21, e921840.	0.8	1
926	A Simple and Practical Guide for Triaging Lymphocyte-rich Effusions for Ancillary Studies. Advances in Anatomic Pathology, 2021, 28, 94-104.	4.3	3
927	Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with WaldenstrÃ¶m's Macroglobulinemia. American Health and Drug Benefits, 2016, 9, 89-92.	0.5	9
928	Concomitant lymphoplasmacytic lymphoma and plasma cell myeloma, a diagnostic challenge. American Journal of Blood Research, 2017, 7, 10-17.	0.6	6
929	Lack of Associations between TLR9 and MYD88 Gene Polymorphisms and Risk of Chronic Lymphocytic Leukemia. Asian Pacific Journal of Cancer Prevention, 2017, 18, 3245-3250.	1.2	2
938	How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen. Current Oncology, 2021, 28, 4611-4633.	2.2	4
939	Advances in Lymphoma Molecular Diagnostics. Diagnostics, 2021, 11, 2174.	2.6	3
940	Venetoclax in Previously Treated WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2022, 40, 63-71.	1.6	53
941	Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. Blood Advances, 2022, 6, 189-199.	5.2	10
942	A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform. Modern Pathology, 2022, 35, 632-639.	5.5	6
943	Bing-Neel Syndrome: An Initial Manifestation of Waldenstrom Macroglobulinemia. Cureus, 2021, 13, e19402.	0.5	0

#	Article	IF	Citations
944	Molecular Profiling and Minimal Residual Disease Monitoring in Multiple Myeloma Patients: A Literature Review. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2021, 14, 436-443.	0.4	0
945	Mature Lymphoid Neoplasms. , 2020, , 245-282.		0
946	Clinicoradiopathological correlation of symptomatic focal bone marrow lesions in WaldenstrÃ¶m Macroglobulinaemia. Leukemia and Lymphoma, 2022, , 1-4.	1.3	2
947	Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/WaldenstrÃ¶m Macroglobulinemia. Frontiers in Oncology, 2021, 11, 801124.	2.8	1
948	Cleavage-Mediated Regulation of Myd88 Signaling by Inflammasome-Activated Caspase-1. Frontiers in Immunology, 2021, 12, 790258.	4.8	3
949	Towards precision medicine in lymphoid malignancies. Journal of Internal Medicine, 2022, 292, 221-242.	6.0	9
950	MYD88^{L265P}and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. Therapeutic Advances in Hematology, 2022, 13, 204062072110728.	2.5	11
951	Diagnosis and management of WaldenstrÃ¶m macroglobulinaemiaâ€"A British Society for Haematology guideline. British Journal of Haematology, 2022, 197, 171-187.	2.5	30
952	KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders. Cancers, 2022, 14, 666.	3.7	8
953	Current approach to WaldenstrÃ¶m Macroglobulinemia. Cancer Treatment and Research Communications, 2022, 31, 100527.	1.7	8
954	Response and survival predictors in a cohort of 319 patients with WaldenstrÃ¶m macroglobulinemia treated with ibrutinib monotherapy. Blood Advances, 2022, 6, 1015-1024.	5.2	12
955	Successful treatment with bortezomib for refractory fever associated with myelodysplastic syndrome with underlying lymphoplasmacytic lymphoma. Clinical Case Reports (discontinued), 2022, 10, e05372.	0.5	0
956	Mast cell density and its clinical relevance in WaldenstrÃ¶m's macroglobulinemia. EJHaem, 2022, 3, 371-378.	1.0	1
957	Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression. European Journal of Case Reports in Internal Medicine, 2022, 9, 003106.	0.4	1
958	Primary central nervous system diffuse large Bâ€cell lymphoma masqueraded as Bingâ€Neel syndrome: Steps in management and review of future directions. Clinical Case Reports (discontinued), 2021, 9, e05113.	0.5	1
960	Bruton's Tyrosine Kinase Inhibitors for the Treatment of WaldenstrÃ¶m's Macroglobulinaemia: A Canadian Perspective. Touch Reviews in Oncology & Haematology, 2021, 17, 73.	0.2	0
961	Use of BTK inhibitors with special focus on ibrutinib in WaldenstrÃ¶m macroglobulinemia: An expert panel opinion statement. Hematological Oncology, 2022, 40, 332-340.	1.7	3
962	Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity. Frontiers in Immunology, 2022, 13, 812774.	4.8	157

#	Article	IF	Citations
963	The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. Clinical and Experimental Medicine, 2023, 23, 255-272.	3.6	11
964	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Advances, 2022, 6, 3332-3338.	5.2	4
965	Inflammatory WaldenstrÃ¶m's macroglobulinaemia: A French monocentric retrospective study of 67 patients. British Journal of Haematology, 2022, 197, 728-735.	2.5	3
966	When a Monoclonal Gammopathy Is Not Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 655-664.	3.8	2
967	Discriminating between WaldenstrÃ¶m macroglobulinemia and marginal zone lymphoma using logistic LASSO regression. Leukemia and Lymphoma, 2022, 63, 1070-1079.	1.3	8
968	Clinical characteristic and outcome of lymphoplasmacytic lymphoma of nonâ€Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study. British Journal of Haematology, 2022, 196, 1362-1368.	2.5	3
969	Somatic mutations in rheumatological diseases: VEXAS syndrome and beyond. Rheumatology, 2022, 61, 3149-3160.	1.9	16
970	Macroglobulinemia and autoinflammatory disease. Rheumatology and Immunology Research, 2021, 2, 227-232.	0.8	1
971	NFâ€ºB signaling in inflammation and cancer. MedComm, 2021, 2, 618-653.	7.2	107
973	Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert Review of Anticancer Therapy, 2022, , .	2.4	3
974	Nucleic Acid Biomarkers in WaldenstrÃ¶m Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance. Diagnostics, 2022, 12, 969.	2.6	5
975	Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. Expert Review of Hematology, 2022, 15, 321-331.	2.2	7
976	MLL1 inhibition reduces IgM levels in WaldenstrÃ¶m macroglobulinemia. Leukemia Research, 2022, 116, 106841.	0.8	2
977	Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation. Human Pathology, 2022, 124, 67-75.	2.0	4
997	Retinopathy Associated with Blood Disorders. , 2022, , 3125-3144.		0
998	Monoclonal antibody-based therapies for WaldenstrÃ¶m's macroglobulinemia. Leukemia Research Reports, 2022, 17, 100324.	0.4	1
999	Treatment paradigm in WaldenstrÃ¶m macroglobulinemia: frontline therapy and beyond. Therapeutic Advances in Hematology, 2022, 13, 204062072210939.	2.5	4
1000	The Use of Bruton Tyrosine Kinase Inhibitors in WaldenstrÃ¶mâ€™s Macroglobulinemia. Journal of Personalized Medicine, 2022, 12, 676.	2.5	0

#	Article	IF	Citations
1001	An Extended Prognostic Index of the ISSWM Score Based on Thyroid Complications in WaldenstrÃ¶m Macroglobulinemia/Lymphoplasmacytoid Lymphoma. Frontiers in Oncology, 2022, 12, .	2.8	1
1002	Bing-Neel Syndrome Successfully Treated with Tirabrutinib. Internal Medicine, 2022, 61, 3575-3579.	0.7	5
1003	MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. International Journal of Molecular Sciences, 2022, 23, 5570.	4.1	14
1004	The Use of Bruton Tyrosine Kinase Inhibitors in WaldenstrÃ¶mâ€™s Macroglobulinemia. Clinical Hematology International, 2022, 4, 21-29.	1.7	1
1005	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	1.4	512
1006	Application of precision medicine in clinical routine in haematologyâ€"Challenges and opportunities. Journal of Internal Medicine, 2022, 292, 243-261.	6.0	12
1008	Immunoglobulin M Monoclonal Gammopathies of Clinical Significance. Frontiers in Oncology, 0, 12, .	2.8	5
1009	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia, 2022, 36, 1720-1748.	7.2	1,023
1011	IgM monoclonal gammopathies of clinical significance: diagnosis and management. Haematologica, 2022, 107, 2037-2050.	3.5	27
1012	Bing-Neel Syndrome: Real-Life Experience in Personalized Diagnostic Approach and Treatment. Frontiers in Oncology, 0, 12, .	2.8	0
1013	Hemophagocytic lymphohistiocytosis as an onset of diffuse large Bâ€'cell lymphoma: A case report. Oncology Letters, 2022, 24, .	1.8	0
1014	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood Advances, 2022, 6, 5210-5221.	5.2	2
1015	Dutch Physicianâ€™s Perspectives on Diagnosis and Treatment of WaldenstrÃ¶mâ€™s Macroglobulinemia Before and After the Implementation of a National Guideline. HemaSphere, 2022, 6, e746.	2.7	0
1016	Bleeding Propensity in WaldenstrÃ¶m Macroglobulinemia: Potential Causes and Evaluation. Thrombosis and Haemostasis, 2022, 122, 1843-1857.	3.4	3
1017	Differential Diagnosis of WaldenstrÃ¶mâ€™s Macroglobulinemia and Early Management: Perspectives from Clinical Practice. Blood and Lymphatic Cancer: Targets and Therapy, 0, Volume 12, 107-117.	2.7	5
1018	Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma. Diagnostic Pathology, 2022, 17, .	2.0	1
1019	Genomic profiling for clinical decision making in lymphoid neoplasms. Blood, 2022, 140, 2193-2227.	1.4	63
1020	Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study. JCO Global Oncology, 2022, , .	1.8	3

#	Article	IF	Citations
1021	Plasma cells arise from differentiation of clonal lymphocytes and secrete IgM in WaldenstrÃ¶m macroglobulinemia. IScience, 2022, 25, 104856.	4.1	1
1022	EXABS-193-IBCL Using Biology to Determine Type and Duration of Treatment in WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, S87-S88.	0.4	0
1023	The role of B cells in the development, progression, and treatment of lymphomas and solid tumors. Advances in Immunology, 2022, , 71-117.	2.2	0
1024	Successful treatment with tirabrutinib for relapsed Bing-Neel syndrome following high-dose methotrexate and craniospinal irradiation. Journal of Clinical and Experimental Hematopathology: JCEH, 2022, 62, 181-186.	0.8	3
1025	WaldenstrÃ¶m Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies. International Journal of Molecular Sciences, 2022, 23, 11145.	4.1	4
1026	Molecular Monitoring of Lymphomas. Annual Review of Pathology: Mechanisms of Disease, 2023, 18, .	22.4	3
1027	Cold Agglutinin Disease: Improved Understanding of Pathogenesis Helps Define Targets for Therapy. Hemato, 2022, 3, 574-594.	0.6	4
1029	Systemic Presentation of Somatic TET2 Mutated B-Cell Lymphoma in a Child With Kabuki Syndrome and a Germline KMT2D Variant. American Journal of Clinical Pathology, 0, , .	0.7	0
1030	Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: A diagnostic dilemma. Useful clinicopathological features to accurate the diagnosis. EJHaem, 2022, 3, 1181-1187.	1.0	2
1031	II. The Update of the Classification of Malignant Lymphomas. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 1392-1403.	0.0	0
1032	Prognostic impact of <scp>MYD88</scp> and <scp>CXCR4</scp> mutations assessed by droplet digital polymerase chain reaction in <scp>IgM</scp> monoclonal gammopathy of undetermined significance and smouldering WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2023, 200, 187-196.	2.5	9
1034	Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in WaldenstrÃ¶m Macroglobulinemia. Cells, 2022, 11, 3287.	4.1	4
1035	First-Line Treatment of WaldenstrÃ¶mâ€™s Macroglobulinaemia: Considerations Based on the Dutch National Guideline. Hemato, 2022, 3, 704-717.	0.6	0
1036	Should Patients with WaldenstrÃ¶m Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?. Hemato, 2022, 3, 689-703.	0.6	0
1037	Polyneuropathy Associated with IgM Monoclonal Gammopathy; Advances in Genetics and Treatment, Focusing on Anti-MAG Antibodies. Hemato, 2022, 3, 663-688.	0.6	1
1038	Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in WaldenstrÃ¶m macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib. Journal of Molecular Modeling, 2022, 28, .	1.8	1
1040	Treatment of relapsed and refractory Waldenstrom Macroglobulinemia. Leukemia and Lymphoma, 0, , 1-12.	1.3	1
1041	Liquid Biopsy in Cancer: Focus on Lymphoproliferative Disorders. Cancers, 2022, 14, 5378.	3.7	1

#	Article	IF	Citations
1042	Paraproteinemia in Autoinflammatory Diseases. , 2022, , 305-316.		0
1043	Monoclonal Gammopathy of Renal Significance: An Insight. , 2022, , 193-209.		0
1044	Recurrent missense variants in clonal hematopoiesisâ€related genes present in the general population. Clinical Genetics, 2023, 103, 247-251.	2.0	2
1045	WaldenstrÃ¶m Macroglobulinemia Whole Genome Reveals Prolonged Germinal Center Activity and Late Copy Number Aberrations. Blood Advances, 0, , .	5.2	1
1046	Intraocular Lymphoma. , 2022, , .		0
1047	Diagnostics in WaldenstrÃ¶mâ€™s macroglobulinemia: a consensus statement of the European Consortium for WaldenstrÃ¶mâ€™s Macroglobulinemia. Leukemia, 2023, 37, 388-395.	7.2	10
1048	Bingâ€“Neel Syndrome: Update on Diagnosis and Treatment. Hemato, 2022, 3, 758-770.	0.6	0
1049	Bruton tyrosine kinase inhibitors in the management of WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2023, 98, 338-347.	4.1	5
1050	Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in WaldenstrÃ¶m macroglobulinemia. Journal of Translational Medicine, 2022, 20, .	4.4	6
1051	Dermatologic Manifestations of Noninflammasome-Mediated Autoinflammatory Diseases. JID Innovations, 2023, 3, 100176.	2.4	3
1052	Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies. Clinical Cancer Research, 2023, 29, 957-970.	7.0	2
1053	Dysfunctions of innate and adaptive immune tumor microenvironment in WaldenstrÃ¶m macroglobulinemia. International Journal of Cancer, 2023, 152, 1947-1963.	5.1	3
1054	Genomic landscape of mature B-cell non-Hodgkin lymphomas â€" an appraisal from lymphomagenesis to drug resistance. Journal of the Egyptian National Cancer Institute, 2022, 34, .	1.5	0
1055	A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. Leukemia, 2023, 37, 18-34.	7.2	21
1056	CK2Î²-regulated signaling controls B cell differentiation and function. Frontiers in Immunology, 0, 13, .	4.8	1
1057	Bone Involvement as a Primary Rare Manifestation of Waldenstrom Macroglobulinemia: A Case Report and Prevalence in a Nationwide Population-Based Cohort Study. Journal of Hematology (Brossard,) Tj ETQq1 1 0.784314 rgBT /Overlo		
1058	Ibrutinib in relapsed/refractory patients with WaldenstrÃ¶m macroglobulinemia: a real-life, retrospective study on behalf of the â€œRTLâ€•(regional Tuscan lymphoma network). Annals of Hematology, 0, , .	1.8	1
1059	Lymphoplasmacytic lymphoma with IgG-Î² paraproteinemia presenting as a hepatic bulky mass. Journal of Clinical and Experimental Hematopathology: JCEH, 2022, 62, 273-278.	0.8	0

#	Article	IF	Citations
1060	Bleeding in the Setting of Lymphoma, with aÂFocus on WaldenstrÃ¶m Macroglobulinaemia. , 2022, , .		0
1061	Management of Marginal Zone Lymphoma: A Canadian Perspective. Current Oncology, 2023, 30, 1745-1759.	2.2	0
1062	Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges. International Journal of Hematologic Oncology, 2023, 12, .	1.6	1
1063	The NF-ÎºB multidimer system model: A knowledge base to explore diverse biological contexts. Science Signaling, 2023, 16, .	3.6	6
1064	WaldenstrÃ¶m Macroglobulinemia and Non-IgM-Type Lymphoplasmacytic Lymphoma Are Genetically Similar. Acta Haematologica, 2023, 146, 384-390.	1.4	0
1065	Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?. Frontiers in Oncology, 0, 13, .	2.8	0
1066	Diagnostic, Prognostic, and Predictive Role of Next-Generation Sequencing in Mature Lymphoid Neoplasms. Surgical Pathology Clinics, 2023, , .	1.7	0
1067	Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-ÎºB Signaling. International Journal of Molecular Sciences, 2023, 24, 5623.	4.1	5
1068	Lymphoplasmacytic Lymphoma with Paraprotein IgG. , 2022, 18, 131-134.		0
1069	Multimodal Imaging Characteristics and Risk Factors Analysis of WaldenstrÃ¶m Macroglobulinemia Retinopathy. American Journal of Ophthalmology, 2023, 253, 233-242.	3.3	0
1070	Report of consensus panel 7 from the 11th international workshop on WaldenstrÃ¶m macroglobulinemia on priorities for novel clinical trials. Seminars in Hematology, 2023, , .	3.4	0
1071	The epidemiology of WaldenstrÃ¶m macroglobulinemia. Seminars in Hematology, 2023, 60, 65-72.	3.4	4
1072	Lymphomas. , 2023, , 1000-1013.		0
1073	Report of Consensus Panel 3 from the 11th International workshop on WaldenstrÃ¶m's Macroglobulinemia: Recommendations for molecular diagnosis in WaldenstrÃ¶m's Macroglobulinemia. Seminars in Hematology, 2023, 60, 90-96.	3.4	3
1074	MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring. Methods in Molecular Biology, 2023, , 57-72.	0.9	0
1075	The Management of Relapsed or Refractory WaldenstrÃ¶mâ€™s Macroglobulinemia. Hematology/Oncology Clinics of North America, 2023, , .	2.2	1
1078	Unmet clinical needs in the use of zanubrutinib in malignant lymphomas (WaldenstrÃ¶m) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 107 Td (paper from an ad hoc expert panel. Hematological Oncology, 2023, 41, 795-808.	1.7	0
1079	Clinical Implications of Genomic Profile in WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2023, 37, 659-670.	2.2	0

#	Article	IF	Citations
1080	WaldenstrÃ¶m macroglobulinemia with secondary pure red cell aplasia in a patient with metastatic castrate resistant prostate cancer receiving an immune checkpoint inhibitor: a case report. Journal of Medical Case Reports, 2023, 17, .	0.8	2
1081	The Histopathology of Cold Agglutinin Diseaseâ€“Associated B-Cell Lymphoproliferative Disease. American Journal of Clinical Pathology, 2023, 160, 229-237.	0.7	1
1082	Exome and targeted sequencing in clinical oncology- Diffuse large B-cell lymphoma as a model. , 2024, , 19-35.		0
1083	BTK Inhibitors in the Frontline Management of WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2023, 37, 707-717.	2.2	2
1084	MYD88 L265P mutation in neurologic autoimmunity without evidence of malignancy. Multiple Sclerosis and Related Disorders, 2023, 77, 104868.	2.0	0
1085	WaldenstrÃ¶m macroglobulinemia: a review of pathogenesis, current treatment, and future prospects. Annals of Hematology, 0, , .	1.8	1
1086	Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review. Experimental Hematology and Oncology, 2023, 12, .	5.0	1
1087	Tailoring therapy in WaldenstrÃ¶m Macroglobulinemia. , 0, , .		0
1088	Clonal architecture and evolutionary history of WaldenstrÃ¶m's macroglobulinemia at the single-cell level. DMM Disease Models and Mechanisms, 0, , .	2.4	0
1089	Leukemic Involvement Is a Common Feature in WaldenstrÃ¶m Macroglobulinemia at Diagnosis. Cancers, 2023, 15, 4152.	3.7	0
1090	VEXAS syndrome: Current clinical, diagnostic and treatment approaches. Intractable and Rare Diseases Research, 2023, , .	0.9	0
1091	The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain. Blood Cancer Journal, 2023, 13, .	6.2	1
1092	Waldenstrom's macroglobulinemia-like B cell lymphoma with MYD88 L265P mutation and t(14;18)(q32;q21) involving IGH-MALT1. Leukemia Research Reports, 2023, 20, 100389.	0.4	0
1093	Diagnosis and Molecular Pathology of Lymphoblastic Leukemias and Lymphomas in the Era of Genomics and Precision Medicine: Historical Evolution and Current Conceptsâ€”Part 3: Mature Leukemias/Lymphomas. , 2023, 1, 155-219.		0
1094	MYD88 Wild Type in IgM Monoclonal Gammopathies: From Molecular Mechanisms to Clinical Challenges. Hemato, 2023, 4, 259-272.	0.6	0
1095	Biomarkers of Progression and Risk Stratification in Asymptomatic WaldenstrÃ¶m Macroglobulinemia. Hematology/Oncology Clinics of North America, 2023, 37, e1-e13.	2.2	0
1096	Analysis of genomic alterations in primary central nervous system lymphoma. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 10	1.0	0
1097	Lymphoplasmacytic lymphoma presenting cold agglutinin syndrome: Clonal expansion of KMT2D and IGHV4â€34 mutations after <scp>COVID</scp>â€19. British Journal of Haematology, 0, , .	2.5	0

#	Article	IF	Citations
1098	Machine learning models-based on integration of next-generation sequencing testing and tumor cell sizes improve subtype classification of mature B-cell neoplasms. Frontiers in Oncology, 0, 13, .	2.8	0
1101	Current approach to WaldenstrÃ¶m macroglobulinemia. Blood Reviews, 2023, 62, 101129.	5.7	0
1102	Macroglobulinemiaâ€"An Update. Springer Biographies, 2023, , 367-375.	0.0	0
1103	Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article. Blood and Lymphatic Cancer: Targets and Therapy, 0, Volume 13, 33-57.	2.7	0
1104	Ibrutinib in therapy of Waldenstromâ€™s macroglobulinemia: literature review and clinical observation. , 2023, 3, 18-28.		0
1106	Targeting MyD88: Therapeutic mechanisms and potential applications of the specific inhibitor ST2825. Inflammation Research, 0, , .	4.0	1
1107	GNA13 is a new marker for germinal center-derived B cell lymphomas. , 2023, 2, 100002.		0
1108	Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies. Experimental Hematology and Oncology, 2023, 12, .	5.0	2
1109	Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis. Nature Genetics, 2023, 55, 2149-2159.	21.4	3
1110	IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies. Frontiers in Immunology, 0, 14, .	4.8	2
1111	Diffuse large B-cell lymphoma with continuously elevated immunoglobulin M following treatment: a case report with pathologic, immunophenotypic, and molecular analyses. Frontiers in Genetics, 0, 14, .	2.3	0
1112	New developments in the diagnosis and characterization of WaldenstrÃ¶mâ€™s macroglobulinemia. Expert Review of Hematology, 2023, 16, 835-847.	2.2	1
1113	Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naÃ¯ve WaldenstrÃ¶m macroglobulinemia. Blood, 2024, 143, 582-591.	1.4	1
1114	Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/WaldenstrÃ¶m Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma. HemaSphere, 2023, 7, e976.	2.7	0
1115	Synthesis and Biological Evaluation of Oxindole Sulfonamide Derivatives as Bruton's Tyrosine Kinase Inhibitors**. ChemMedChem, 2024, 19, .	3.2	1
1116	Lymphoplasmacytic lymphoma and HIV: A case report. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2024, 8, 42-46.	0.5	0
1117	Hematologic secondary malignancies among 102 Chinese patients with Waldenstromâ€™s macroglobulinemia: a single-center case experience and literature review. Frontiers in Oncology, 0, 13, .	2.8	0
1118	Hematologic Malignancies. , 2023, , 5-21.		0

#	Article	IF	Citations
1119	WaldenstrÃ¶m Macroglobulinemia: Targeted Agents Taking Center Stage. Drugs, 0, , .	10.9	1
1120	å…ç–«ä»‹åœ¨æ€§ãƒ‹ãƒ¥ãƒ¼ãƒãƒ'ãƒãƒ¼ã®æ–°è¦æ²»ç™‚å±•æœ›. Clinical Neurology, 2023, , .	0.1	0
1121	Diffuse Large B-Cell Lymphoma. , 2023, , .		0
1122	Nonviral cryoglobulinemic vasculitis: an updated review for clinical practice. Vessel Plus, 0, , .	0.4	0
1123	Multiple Genomic Alterations, Including a Novel AFF4::IRF1 Fusion Gene, in a Treatment-Refractory Blastic Plasmacytoid Dendritic-Cell Neoplasm: A Case Report and Literature Review. International Journal of Molecular Sciences, 2024, 25, 305.	4.1	0
1124	Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UKâ€™s Haematological Malignancy Research Network. Cancer Epidemiology, 2024, 88, 102513.	1.9	1
1125	Molekulargenetik bei indolenten Lymphomen. , 2023, , 5-22.		0
1126	WaldenstrÃ¶m-MakroglobulinÃmie. , 2023, , 157-177.		0
1127	Precision of diagnostic approaches and individualized therapy toward improving patient outcomes. , 2024, , 173-194.		0
1128	A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS. Seminars in Hematology, 2024, 61, 43-50.	3.4	0
1129	Primary lymphoplasmacytic lymphoma of the larynx mimicking extramedullary plasmacytoma: A case report. Oncology Letters, 2024, 27, .	1.8	0
1130	Waldenstrom Macroglobulinemia. , 2024, , .		0
1131	Singleâ€cell analysis of MYD88^{L265P} and MYD88^{WT} WaldenstrÃ¶m macroglobulinemia patients. HemaSphere, 2024, 8, .	2.7	0
1132	The impact of MYD88 and PIM1 in mature large B-cell non-Hodgkin lymphomas: Defining element of their evolution and prognosis. Medicine (United States), 2024, 103, e36269.	1.0	0
1133	Circulating tumor cells in WaldenstrÃ¶m macroglobulinemia. Leukemia, 2024, 38, 903-907.	7.2	0
1134	Mutational landscape in WaldenstrÃ¶m macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice. Leukemia and Lymphoma, 0, , 1-10.	1.3	0
1135	Introduction to Next-Generation Sequencing. Molecular Pathology Library, 2023, , 47-82.	0.1	0
1136	Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer. , 0, 3, .		0

#	Article	IF	Citations
1137	<scp>PlentiPlex</scp>â„¢ <scp>MYD88</scp> WaldenstrÃ¶m lymphoma <scp>qPCR</scp> assay: A highly sensitive method for detection of <scp>MYD88 L265P</scp> mutation. International Journal of Laboratory Hematology, 0, , .	1.3	0
1138	Paraproteinemiaâ€associated neuropathy with or without <scp>antiâ€</scp>myelinâ€associated glycoprotein antibody. Clinical and Experimental Neuroimmunology, 0, , .	1.0	0
1139	Waldenstrom macroglobulinaemia with <scp>AA</scp> amyloidosis reveals a Bâ€cellâ€restricted NLRP2 variant. British Journal of Haematology, 0, , .	2.5	0
1141	Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review. Leukemia and Lymphoma, 0, , 1-7.	1.3	0
1142	Navigating Lymphomas through BCR Signaling and Double-Hit Insights: Overview. Hematology Reports, 2024, 16, 164-178.	0.8	0